<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="XELODA">
  <Text>
    <Section id="S1" name="adverse reactions">  6 ADVERSE REACTIONS

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

   EXCERPT:   Most common adverse reactions (&gt;=30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. Other adverse reactions, including serious adverse reactions, have been reported. (  6  )

   To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  

 

  6.1 Adjuvant Colon Cancer

      Table 4    shows the adverse reactions occurring in &gt;=5% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment. A total of 995 patients were treated with 1250 mg/m  2  twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 974 patients were administered 5-FU and leucovorin (20 mg/m  2  leucovorin IV followed by 425 mg/m  2  IV bolus 5-FU on days 1-5 every 28 days). The median duration of treatment was 164 days for capecitabine-treated patients and 145 days for 5-FU/LV-treated patients. A total of 112 (11%) and 73 (7%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions. A total of 18 deaths due to all causes occurred either on study or within 28 days of receiving study drug: 8 (0.8%) patients randomized to XELODA and 10 (1.0%) randomized to 5-FU/LV.

     Table 5    shows grade 3/4 laboratory abnormalities occurring in &gt;=1% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment.

 Table 4 Percent Incidence of Adverse Reactions Reported in &gt;=5% of Patients Treated With XELODA or 5-FU/LV for Colon Cancer in the Adjuvant Setting (Safety Population) 
                                   Adjuvant Treatment for Colon Cancer (N=1969)   
                                     XELODA(N=995)     5-FU/LV(N=974)     
 Body System/Adverse Event            All Grades          Grade 3/4         All Grades          Grade 3/4       
  
   Gastrointestinal Disorders                                                                                   
   Diarrhea                               47                 12                 65                 14           
   Nausea                                 34                  2                 47                  2           
   Stomatitis                             22                  2                 60                 14           
   Vomiting                               15                  2                 21                  2           
   Abdominal Pain                         14                  3                 16                  2           
   Constipation                            9                  -                 11                 &lt;1           
   Upper Abdominal Pain                    7                 &lt;1                  7                 &lt;1           
   Dyspepsia                               6                 &lt;1                  5                  -           
   Skin and Subcutaneous Tissue Disorders                                                                                 
   Hand-and-Foot Syndrome                 60                 17                  9                 &lt;1           
   Alopecia                                6                  -                 22                 &lt;1           
   Rash                                    7                  -                  8                  -           
   Erythema                                6                  1                  5                 &lt;1           
   General Disorders and Administration Site Conditions                                                                                 
   Fatigue                                16                 &lt;1                 16                  1           
   Pyrexia                                 7                 &lt;1                  9                 &lt;1           
   Asthenia                               10                 &lt;1                 10                  1           
   Lethargy                               10                 &lt;1                  9                 &lt;1           
   Nervous System Disorders                                                                                     
   Dizziness                               6                 &lt;1                  6                  -           
   Headache                                5                 &lt;1                  6                 &lt;1           
   Dysgeusia                               6                  -                  9                  -           
   Metabolism and Nutrition Disorders                                                                                 
   Anorexia                                9                 &lt;1                 11                 &lt;1           
   Eye Disorders                                                                                                
   Conjunctivitis                          5                 &lt;1                  6                 &lt;1           
   Blood and Lymphatic System Disorders                                                                                 
   Neutropenia                             2                 &lt;1                  8                  5           
   Respiratory Thoracic and Mediastinal Disorders                                                                                 
   Epistaxis                               2                  -                  5                  -           
          Table 5 Percent Incidence of Grade 3/4 Laboratory Abnormalities Reported in &gt;=1% of Patients Receiving XELODA Monotherapy for Adjuvant Treatment of Colon Cancer (Safety Population) 
 Adverse Event                                                 XELODA(n=995)Grade 3/4 %  IV 5-FU/LV(n=974)Grade 3/4 %   
  
   Increased ALAT (SGPT)                                               1.6                   0.6            
   Increased calcium                                                   1.1                   0.7            
   Decreased calcium                                                   2.3                   2.2            
   Decreased hemoglobin                                                1.0                   1.2            
   Decreased lymphocytes                                               13.0                  13.0           
   Decreased neutrophils [note: The incidence of grade 3/4 white blood cell abnormalities was 1.3% in the XELODA arm and 4.9% in the IV 5-FU/LV arm.]           2.2                   26.2           
   Decreased neutrophils/granulocytes                                  2.4                   26.4           
   Decreased platelets                                                 1.0                   0.7            
   Increased bilirubin [note: It should be noted that grading was according to NCIC CTC Version 1 (May, 1994). In the NCIC-CTC Version 1, hyperbilirubinemia grade 3 indicates a bilirubin value of 1.5 to 3.0 * upper limit of normal (ULN) range, and grade 4 a value of &gt; 3.0 * ULN. The NCI CTC Version 2 and above define a grade 3 bilirubin value of &gt;3.0 to 10.0 * ULN, and grade 4 values &gt;10.0 * ULN.]            20                   6.3            
           6.2 Metastatic Colorectal Cancer
     Monotherapy  

     Table 6    shows the adverse reactions occurring in &gt;=5% of patients from pooling the two phase 3 trials in first line metastatic colorectal cancer. A total of 596 patients with metastatic colorectal cancer were treated with 1250 mg/m  2  twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 593 patients were administered 5-FU and leucovorin in the Mayo regimen (20 mg/m  2  leucovorin IV followed by 425 mg/m  2  IV bolus 5-FU, on days 1-5, every 28 days). In the pooled colorectal database the median duration of treatment was 139 days for capecitabine-treated patients and 140 days for 5-FU/LV-treated patients. A total of 78 (13%) and 63 (11%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions/intercurrent illness. A total of 82 deaths due to all causes occurred either on study or within 28 days of receiving study drug: 50 (8.4%) patients randomized to XELODA and 32 (5.4%) randomized to 5-FU/LV.

 Table 6 Pooled Phase 3 Colorectal Trials: Percent Incidence of Adverse Reactions in &gt;=5% of Patients 
 Adverse Event                             XELODA(n=596)  5-FU/LV(n=593)   
                                             Total%     Grade 3%    Grade 4%     Total%     Grade 3%    Grade 4%    
  
 - Not observed                             
 NA = Not Applicable                        
  
   Number of Patients With &gt; One Adverse Event        96          52          9           94          45          9        
   Body System/Adverse Event                                                                                        
   GI                                                                                                               
   Diarrhea                                    55          13          2           61          10          2        
   Nausea                                      43          4           -           51          3           &lt;1       
   Vomiting                                    27          4           &lt;1          30          4           &lt;1       
   Stomatitis                                  25          2           &lt;1          62          14          1        
   Abdominal Pain                              35          9           &lt;1          31          5           -        
   Gastrointestinal Motility Disorder          10          &lt;1          -           7           &lt;1          -        
   Constipation                                14          1           &lt;1          17          1           -        
   Oral Discomfort                             10          -           -           10          -           -        
   Upper GI Inflammatory Disorders             8           &lt;1          -           10          1           -        
   Gastrointestinal Hemorrhage                 6           1           &lt;1          3           1           -        
   Ileus                                       6           4           1           5           2           1        
   Skin and Subcutaneous                                                                                            
   Hand-and-Foot Syndrome                      54          17          NA          6           1           NA       
   Dermatitis                                  27          1           -           26          1           -        
   Skin Discoloration                          7           &lt;1          -           5           -           -        
   Alopecia                                    6           -           -           21          &lt;1          -        
   General                                                                                                          
   Fatigue/Weakness                            42          4           -           46          4           -        
   Pyrexia                                     18          1           -           21          2           -        
   Edema                                       15          1           -           9           1           -        
   Pain                                        12          1           -           10          1           -        
   Chest Pain                                  6           1           -           6           1           &lt;1       
   Neurological                                                                                                     
   Peripheral Sensory Neuropathy               10          -           -           4           -           -        
   Headache                                    10          1           -           7           -           -        
   Dizziness [note: Excluding vertigo]         8           &lt;1          -           8           &lt;1          -        
   Insomnia                                    7           -           -           7           -           -        
   Taste Disturbance                           6           1           -           11          &lt;1          1        
   Metabolism                                                                                                       
   Appetite Decreased                          26          3           &lt;1          31          2           &lt;1       
   Dehydration                                 7           2           &lt;1          8           3           1        
   Eye                                                                                                              
   Eye Irritation                              13          -           -           10          &lt;1          -        
   Vision Abnormal                             5           -           -           2           -           -        
   Respiratory                                                                                                      
   Dyspnea                                     14          1           -           10          &lt;1          1        
   Cough                                       7           &lt;1          1           8           -           -        
   Pharyngeal Disorder                         5           -           -           5           -           -        
   Epistaxis                                   3           &lt;1          -           6           -           -        
   Sore Throat                                 2           -           -           6           -           -        
   Musculoskeletal                                                                                                  
   Back Pain                                   10          2           -           9           &lt;1          -        
   Arthralgia                                  8           1           -           6           1           -        
   Vascular                                                                                                         
   Venous Thrombosis                           8           3           &lt;1          6           2           -        
   Psychiatric                                                                                                      
   Mood Alteration                             5           -           -           6           &lt;1          -        
   Depression                                  5           -           -           4           &lt;1          -        
   Infections                                                                                                       
   Viral                                       5           &lt;1          -           5           &lt;1          -        
   Blood and Lymphatic                                                                                              
   Anemia                                      80          2           &lt;1          79          1           &lt;1       
   Neutropenia                                 13          1           2           46          8           13       
   Hepatobiliary                                                                                                    
   Hyperbilirubinemia                          48          18          5           17          3           3        
               6.3 Breast Cancer
     In Combination with Docetaxel  

 The following data are shown for the combination study with XELODA and docetaxel in patients with metastatic breast cancer in    Table 7    and    Table 8    . In the XELODA and docetaxel combination arm the treatment was XELODA administered orally 1250 mg/m  2  twice daily as intermittent therapy (2 weeks of treatment followed by 1 week without treatment) for at least 6 weeks and docetaxel administered as a 1-hour intravenous infusion at a dose of 75 mg/m  2  on the first day of each 3-week cycle for at least 6 weeks. In the monotherapy arm docetaxel was administered as a 1-hour intravenous infusion at a dose of 100 mg/m  2  on the first day of each 3-week cycle for at least 6 weeks. The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm. A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse reactions. The percentage of patients requiring dose reductions due to adverse reactions was 65% in the combination arm and 36% in the monotherapy arm. The percentage of patients requiring treatment interruptions due to adverse reactions in the combination arm was 79%. Treatment interruptions were part of the dose modification scheme for the combination therapy arm but not for the docetaxel monotherapy-treated patients.

 Table 7 Percent Incidence of Adverse Events Considered Related or Unrelated to Treatment in &gt;=5% of Patients Participating in the XELODA and Docetaxel Combination vs Docetaxel Monotherapy Study 
 Adverse Event                             XELODA 1250 mg/m  2  /bid With Docetaxel75 mg/m  2  /3 weeks  Docetaxel100 mg/m  2  /3 weeks   
                                            (n=251)     (n=255)     
                                             Total%     Grade 3%    Grade 4%     Total%     Grade 3%    Grade 4%    
  
 - Not observed                             
 NA = Not Applicable                        
  
   Number of Patients With at Least One Adverse Event        99         76.5        29.1         97         57.6        31.8      
   Body System/Adverse Event                                                                                        
   GI                                                                                                               
   Diarrhea                                    67          14          &lt;1          48          5           &lt;1       
   Stomatitis                                  67          17          &lt;1          43          5           -        
   Nausea                                      45          7           -           36          2           -        
   Vomiting                                    35          4           1           24          2           -        
   Constipation                                20          2           -           18          -           -        
   Abdominal Pain                              30          &lt;3          &lt;1          24          2           -        
   Dyspepsia                                   14          -           -           8           1           -        
   Dry Mouth                                   6           &lt;1          -           5           -           -        
   Skin and Subcutaneous                                                                                            
   Hand-and-Foot Syndrome                      63          24          NA          8           1           NA       
   Alopecia                                    41          6           -           42          7           -        
   Nail Disorder                               14          2           -           15          -           -        
   Dermatitis                                  8           -           -           11          1           -        
   Rash Erythematous                           9           &lt;1          -           5           -           -        
   Nail Discoloration                          6           -           -           4           &lt;1          -        
   Onycholysis                                 5           1           -           5           1           -        
   Pruritus                                    4           -           -           5           -           -        
   General                                                                                                          
   Pyrexia                                     28          2           -           34          2           -        
   Asthenia                                    26          4           &lt;1          25          6           -        
   Fatigue                                     22          4           -           27          6           -        
   Weakness                                    16          2           -           11          2           -        
   Pain in Limb                                13          &lt;1          -           13          2           -        
   Lethargy                                    7           -           -           6           2           -        
   Pain                                        7           &lt;1          -           5           1           -        
   Chest Pain (non-cardiac)                    4           &lt;1          -           6           2           -        
   Influenza-like Illness                      5           -           -           5           -           -        
   Neurological                                                                                                     
   Taste Disturbance                           16          &lt;1          -           14          &lt;1          -        
   Headache                                    15          3           -           15          2           -        
   Paresthesia                                 12          &lt;1          -           16          1           -        
   Dizziness                                   12          -           -           8           &lt;1          -        
   Insomnia                                    8           -           -           10          &lt;1          -        
   Peripheral Neuropathy                       6           -           -           10          1           -        
   Hypoaesthesia                               4           &lt;1          -           8           &lt;1          -        
   Metabolism                                                                                                       
   Anorexia                                    13          1           -           11          &lt;1          -        
   Appetite Decreased                          10          -           -           5           -           -        
   Weight Decreased                            7           -           -           5           -           -        
   Dehydration                                 10          2           -           7           &lt;1          &lt;1       
   Eye                                                                                                              
   Lacrimation Increased                       12          -           -           7           &lt;1          -        
   Conjunctivitis                              5           -           -           4           -           -        
   Eye Irritation                              5           -           -           1           -           -        
   Musculoskeletal                                                                                                  
   Arthralgia                                  15          2           -           24          3           -        
   Myalgia                                     15          2           -           25          2           -        
   Back Pain                                   12          &lt;1          -           11          3           -        
   Bone Pain                                   8           &lt;1          -           10          2           -        
   Cardiac                                                                                                          
   Edema                                       33          &lt;2          -           34          &lt;3          1        
   Blood                                                                                                            
   Neutropenic Fever                           16          3           13          21          5           16       
   Respiratory                                                                                                      
   Dyspnea                                     14          2           &lt;1          16          2           -        
   Cough                                       13          1           -           22          &lt;1          -        
   Sore Throat                                 12          2           -           11          &lt;1          -        
   Epistaxis                                   7           &lt;1          -           6           -           -        
   Rhinorrhea                                  5           -           -           3           -           -        
   Pleural Effusion                            2           1           -           7           4           -        
   Infection                                                                                                        
   Oral Candidiasis                            7           &lt;1          -           8           &lt;1          -        
   Urinary Tract Infection                     6           &lt;1          -           4           -           -        
   Upper Respiratory Tract                     4           -           -           5           1           -        
   Vascular                                                                                                         
   Flushing                                    5           -           -           5           -           -        
   Lymphoedema                                 3           &lt;1          -           5           1           -        
   Psychiatric                                                                                                      
   Depression                                  5           -           -           5           1           -        
            Table 8 Percent of Patients With Laboratory Abnormalities Participating in the XELODA and Docetaxel Combination vs Docetaxel Monotherapy Study 
 Adverse Event                             XELODA 1250 mg/m  2  /bid With Docetaxel75 mg/m  2  /3 weeks  Docetaxel100 mg/m  2  /3 weeks   
                                            (n=251)     (n=255)     
 Body System/Adverse Event                   Total%     Grade 3%    Grade 4%     Total%     Grade 3%    Grade 4%    
  
   Hematologic                                                                                                      
   Leukopenia                                  91          37          24          88          42          33       
   Neutropenia/Granulocytopenia                86          20          49          87          10          66       
   Thrombocytopenia                            41          2           1           23          1           2        
   Anemia                                      80          7           3           83          5           &lt;1       
   Lymphocytopenia                             99          48          41          98          44          40       
   Hepatobiliary                                                                                                    
   Hyperbilirubinemia                          20          7           2           6           2           2        
                 Monotherapy  
 

 The following data are shown for the study in stage IV breast cancer patients who received a dose of 1250 mg/m  2  administered twice daily for 2 weeks followed by a 1-week rest period. The mean duration of treatment was 114 days. A total of 13 out of 162 patients (8%) discontinued treatment because of adverse reactions/intercurrent illness.

 Table 9 Percent Incidence of Adverse Reactions Considered Remotely, Possibly or Probably Related to Treatment in &gt;=5% of Patients Participating in the Single Arm Trial in Stage IV Breast Cancer 
 Adverse Event                                   Phase 2 Trial in Stage IV Breast Cancer(n=162)   
 Body System/Adverse Event                             Total%             Grade 3%            Grade 4%        
  
 - Not observed                                   
 NA = Not Applicable                              
  
   GI                                                                                                         
 Diarrhea                                                57                  12                  3            
 Nausea                                                  53                  4                   -            
 Vomiting                                                37                  4                   -            
 Stomatitis                                              24                  7                   -            
 Abdominal Pain                                          20                  4                   -            
 Constipation                                            15                  1                   -            
 Dyspepsia                                               8                   -                   -            
   Skin and Subcutaneous                                                                                      
 Hand-and-Foot Syndrome                                  57                  11                  NA           
 Dermatitis                                              37                  1                   -            
 Nail Disorder                                           7                   -                   -            
   General                                                                                                    
 Fatigue                                                 41                  8                   -            
 Pyrexia                                                 12                  1                   -            
 Pain in Limb                                            6                   1                   -            
   Neurological                                                                                               
 Paresthesia                                             21                  1                   -            
 Headache                                                9                   1                   -            
 Dizziness                                               8                   -                   -            
 Insomnia                                                8                   -                   -            
   Metabolism                                                                                                 
 Anorexia                                                23                  3                   -            
 Dehydration                                             7                   4                   1            
   Eye                                                                                                        
 Eye Irritation                                          15                  -                   -            
   Musculoskeletal                                                                                            
 Myalgia                                                 9                   -                   -            
   Cardiac                                                                                                    
 Edema                                                   9                   1                   -            
   Blood                                                                                                      
 Neutropenia                                             26                  2                   2            
 Thrombocytopenia                                        24                  3                   1            
 Anemia                                                  72                  3                   1            
 Lymphopenia                                             94                  44                  15           
   Hepatobiliary                                                                                              
 Hyperbilirubinemia                                      22                  9                   2            
            6.4 Clinically Relevant Adverse Events in &lt;5% of Patients
   Clinically relevant adverse events reported in &lt;5% of patients treated with XELODA either as monotherapy or in combination with docetaxel that were considered at least remotely related to treatment are shown below; occurrences of each grade 3 and 4 adverse event are provided in parentheses.

     Monotherapy (Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Metastatic Breast Cancer)  


   Gastrointestinal:    abdominal distension, dysphagia, proctalgia, ascites (0.1%), gastric ulcer (0.1%), ileus (0.3%), toxic dilation of intestine, gastroenteritis (0.1%)   
   Skin &amp; Subcutan.:    nail disorder (0.1%), sweating increased (0.1%), photosensitivity reaction (0.1%), skin ulceration, pruritus, radiation recall syndrome (0.2%)   
   General:            chest pain (0.2%), influenza-like illness, hot flushes, pain (0.1%), hoarseness, irritability, difficulty in walking, thirst, chest mass, collapse, fibrosis (0.1%), hemorrhage, edema, sedation   
   Neurological:       insomnia, ataxia (0.5%), tremor, dysphasia, encephalopathy (0.1%), abnormal coordination, dysarthria, loss of consciousness (0.2%), impaired balance   
   Metabolism:         increased weight, cachexia (0.4%), hypertriglyceridemia (0.1%), hypokalemia, hypomagnesemia   
   Eye:                conjunctivitis                                                                     
   Respiratory:        cough (0.1%), epistaxis (0.1%), asthma (0.2%), hemoptysis, respiratory distress (0.1%), dyspnea   
   Cardiac:            tachycardia (0.1%), bradycardia, atrial fibrillation, ventricular extrasystoles, extrasystoles, myocarditis (0.1%), pericardial effusion   
   Infections:         laryngitis (1.0%), bronchitis (0.2%), pneumonia (0.2%), bronchopneumonia (0.2%), keratoconjunctivitis, sepsis (0.3%), fungal infections (including candidiasis) (0.2%)   
   Musculoskeletal:    myalgia, bone pain (0.1%), arthritis (0.1%), muscle weakness                       
   Blood &amp; Lymphatic:    leukopenia (0.2%), coagulation disorder (0.1%), bone marrow depression (0.1%), idiopathic thrombocytopenia purpura (1.0%), pancytopenia (0.1%)   
   Vascular:           hypotension (0.2%), hypertension (0.1%), lymphoedema (0.1%), pulmonary embolism (0.2%), cerebrovascular accident (0.1%)   
   Psychiatric:        depression, confusion (0.1%)                                                       
   Renal:              renal impairment (0.6%)                                                            
   Ear:                vertigo                                                                            
   Hepatobiliary:      hepatic fibrosis (0.1%), hepatitis (0.1%), cholestatic hepatitis (0.1%), abnormal liver function tests   
   Immune System:      drug hypersensitivity (0.1%)                                                       
   Postmarketing:      hepatic failure, lacrimal duct stenosis, acute renal failure secondary to dehydration including fatal outcome  [see  Warnings and Precautions (5.5)  ]  , cutaneous lupus erythematosus, corneal disorders including keratitis, toxic leukoencephalopathy, severe skin reactions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (TEN)  [see  Warnings and Precautions (5.7)  ]    ,  persistent or severe hand-and-foot syndrome can eventually lead to loss of fingerprints [  see  Warnings and Precautions (5.7)    ]   
            XELODA In Combination With Docetaxel (Metastatic Breast Cancer)  
 


   Gastrointestinal:    ileus (0.4%), necrotizing enterocolitis (0.4%), esophageal ulcer (0.4%), hemorrhagic diarrhea (0.8%)   
   Neurological:       ataxia (0.4%), syncope (1.2%), taste loss (0.8%), polyneuropathy (0.4%), migraine (0.4%)   
   Cardiac:            supraventricular tachycardia (0.4%)                                                
   Infection:          neutropenic sepsis (2.4%), sepsis (0.4%), bronchopneumonia (0.4%)                  
   Blood &amp; Lymphatic:    agranulocytosis (0.4%), prothrombin decreased (0.4%)                               
   Vascular:           hypotension (1.2%), venous phlebitis and thrombophlebitis (0.4%), postural hypotension (0.8%)   
   Renal:              renal failure (0.4%)                                                               
   Hepatobiliary:      jaundice (0.4%), abnormal liver function tests (0.4%), hepatic failure (0.4%), hepatic coma (0.4%), hepatotoxicity (0.4%)   
   Immune System:      hypersensitivity (1.2%)                                                            

</Section>
    <Section id="S2" name="boxed warnings">

    BOXED WARNING: WARNING: XELODA-WARFARIN INTERACTION

    WARNING: XELODA-WARFARIN INTERACTION  

    XELODA Warfarin Interaction: Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored frequently in order to adjust the anticoagulant dose accordingly. A clinically important XELODA-Warfarin drug interaction was demonstrated in a clinical pharmacology trial   [see   Warnings and Precautions (5.2)   and   Drug Interactions (7.1)  ]  . Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking XELODA concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Postmarketing reports have shown clinically significant increases in prothrombin time (PT) and INR in patients who were stabilized on anticoagulants at the time XELODA was introduced. These events occurred within several days and up to several months after initiating XELODA therapy and, in a few cases, within 1 month after stopping XELODA. These events occurred in patients with and without liver metastases. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.  

   EXCERPT:     WARNING: XELODA-WARFARIN INTERACTION  

   See full prescribing information for complete boxed warning.  

   Patients receiving concomitant XELODA and oral coumarin-derivative anticoagulants such as warfarin and phenprocoumon should have their anticoagulant response (INR or prothrombin time) monitored frequently in order to adjust the anticoagulant dose accordingly. Altered coagulation parameters and/or bleeding, including death, have been reported during concomitant use.  

 *  Occurrence: Within several days and up to several months after initiating XELODA therapy; may also be seen within 1 month after stopping XELODA 
 *  Predisposing factors: age&gt;60 and diagnosis of cancer 
    

</Section>
    <Section id="S3" name="warnings and precautions">   5 WARNINGS AND PRECAUTIONS

   EXCERPT:    *   Coagulopathy : May result in bleeding, death. Monitor anticoagulant response (e.g., INR) and adjust anticoagulant dose accordingly. (  5.1  ) 
 *   Diarrhea : May be severe. Interrupt XELODA treatment immediately until diarrhea resolves or decreases to grade 1. Recommend standard antidiarrheal treatments. (  5.2  ) 
 *   Cardiotoxicity : Common in patients with a prior history of coronary artery disease. (  5.3  ) 
 *   Increased Risk of Severe or Fatal Adverse Reactions in Patients with Low or Absent Dihydropyrimidine Dehydrogenase (DPD) Activity: Withhold or permanently discontinue XELODA in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No XELODA dose has been proven safe in patients with absent DPD activity. (  5.4  ) 
 *   Dehydration and Renal Failure : Interrupt XELODA treatment until dehydration is corrected. Potential risk of acute renal failure secondary to dehydration. Monitor and correct dehydration. (  5.5  ). 
 *   Embryo-Fetal Toxicity : Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (  5.6  ,  8.1  ,  8.3  ) 
 *   Mucocutaneous and Dermatologic Toxicity : Severe mucocutaneous reactions, Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. XELODA should be permanently discontinued in patients who experience a severe mucocutaneous reaction during treatment. XELODA may induce hand-and-foot syndrome. Persistent or severe hand-and-foot syndrome can lead to loss of fingerprints which could impact patient identification. Interrupt XELODA treatment until the hand-and-foot syndrome event resolves or decreases in intensity. (  5.7  ) 
 *   Hyperbilirubinemia : Interrupt XELODA treatment immediately until the hyperbilirubinemia resolves or decreases in intensity. (  5.8  ) 
 *   Hematologic : Do not treat patients with neutrophil counts &lt;1.5 * 10  9  /L or thrombocyte counts &lt;100 * 10  9  /L. If grade 3-4 neutropenia or thrombocytopenia occurs, stop therapy until condition resolves. (  5.9  ) 
    
 

   5.1 Coagulopathy

  Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely with great frequency and the anticoagulant dose should be adjusted accordingly [see  Boxed Warning  and  Drug Interactions (7.1)  ].  

    5.2 Diarrhea

  XELODA can induce diarrhea, sometimes severe. Patients with severe diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated. In 875 patients with either metastatic breast or colorectal cancer who received XELODA monotherapy, the median time to first occurrence of grade 2 to 4 diarrhea was 34 days (range from 1 to 369 days). The median duration of grade 3 to 4 diarrhea was 5 days. National Cancer Institute of Canada (NCIC) grade 2 diarrhea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhea as an increase of 7 to 9 stools/day or incontinence and malabsorption, and grade 4 diarrhea as an increase of &gt;=10 stools/day or grossly bloody diarrhea or the need for parenteral support. If grade 2, 3 or 4 diarrhea occurs, administration of XELODA should be immediately interrupted until the diarrhea resolves or decreases in intensity to grade 1 [see  Dosage and Administration (2.3)  ]  . Standard antidiarrheal treatments (e.g., loperamide) are recommended.

 Necrotizing enterocolitis (typhlitis) has been reported.

    5.3 Cardiotoxicity

  The cardiotoxicity observed with XELODA includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease.

    5.4 Dihydropyrimidine Dehydrogenase Deficiency

  Based on postmarketing reports, patients with certain homozygous or certain compound heterozygous mutations in the DPD gene that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by XELODA (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions caused by XELODA.

 Withhold or permanently discontinue XELODA based on clinical assessment of the onset, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No XELODA dose has been proven safe for patients with complete absence of DPD activity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test.

    5.5 Dehydration and Renal Failure

  Dehydration has been observed and may cause acute renal failure which can be fatal. Patients with pre-existing compromised renal function or who are receiving concomitant XELODA with known nephrotoxic agents are at higher risk. Patients with anorexia, asthenia, nausea, vomiting or diarrhea may rapidly become dehydrated. Monitor patients when XELODA is administered to prevent and correct dehydration at the onset. If grade 2 (or higher) dehydration occurs, XELODA treatment should be immediately interrupted and the dehydration corrected. Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled. Dose modifications should be applied for the precipitating adverse event as necessary [ see  Dosage and Administration (2.3)    ].

 Patients with moderate renal impairment at baseline require dose reduction [see  Dosage and Administration (2.4)  ]  . Patients with mild and moderate renal impairment at baseline should be carefully monitored for adverse reactions. Prompt interruption of therapy with subsequent dose adjustments is recommended if a patient develops a grade 2 to 4 adverse event as outlined in   Table 2     [see  Dosage and Administration (2.3)  ,  Use in Specific Populations (8.7)  , and  Clinical Pharmacology (12.3)  ]  .

    5.6 Embryo-Fetal Toxicity

   Based on findings from animal reproduction studies and its mechanism of action, XELODA may cause fetal harm when given to a pregnant woman [see  Clinical Pharmacology (12.1)  ]  . Limited available data are not sufficient to inform use of XELODA in pregnant women. In animal reproduction studies, administration of capecitabine to pregnant animals during the period of organogenesis caused embryolethality and teratogenicity in mice and embryolethality in monkeys at 0.2 and 0.6 times the exposure (AUC) in patients receiving the recommended dose respectively [see  Use in Specific Populations (8.1)  ]  . Apprise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of XELODA [see  Use in Specific Populations (8.3)  ]  .  

    5.7 Mucocutaneous and Dermatologic Toxicity

   Severe mucocutaneous reactions, some with fatal outcome, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis (TEN) can occur in patients treated with XELODA [ see  Adverse Reactions (6.4)    ]. XELODA should be permanently discontinued in patients who experience a severe mucocutaneous reaction possibly attributable to XELODA treatment.  

 Hand-and-foot syndrome (palmar-plantar erythrodysesthesia or chemotherapy-induced acral erythema) is a cutaneous toxicity. Median time to onset was 79 days (range from 11 to 360 days) with a severity range of grades 1 to 3 for patients receiving XELODA monotherapy in the metastatic setting. Grade 1 is characterized by any of the following: numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt normal activities. Grade 2 hand-and-foot syndrome is defined as painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient's activities of daily living. Grade 3 hand-and-foot syndrome is defined as moist desquamation, ulceration, blistering or severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living. Persistent or severe hand-and-foot syndrome (grade 2 and above) can eventually lead to loss of fingerprints which could impact patient identification. If grade 2 or 3 hand-and-foot syndrome occurs, administration of XELODA should be interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, subsequent doses of XELODA should be decreased [see  Dosage and Administration (2.3)  ]  .

    5.8 Hyperbilirubinemia

  In 875 patients with either metastatic breast or colorectal cancer who received at least one dose of XELODA 1250 mg/m  2  twice daily as monotherapy for 2 weeks followed by a 1-week rest period, grade 3 (1.5-3 * ULN) hyperbilirubinemia occurred in 15.2% (n=133) of patients and grade 4 (&gt;3 * ULN) hyperbilirubinemia occurred in 3.9% (n=34) of patients. Of 566 patients who had hepatic metastases at baseline and 309 patients without hepatic metastases at baseline, grade 3 or 4 hyperbilirubinemia occurred in 22.8% and 12.3%, respectively. Of the 167 patients with grade 3 or 4 hyperbilirubinemia, 18.6% (n=31) also had postbaseline elevations (grades 1 to 4, without elevations at baseline) in alkaline phosphatase and 27.5% (n=46) had postbaseline elevations in transaminases at any time (not necessarily concurrent). The majority of these patients, 64.5% (n=20) and 71.7% (n=33), had liver metastases at baseline. In addition, 57.5% (n=96) and 35.3% (n=59) of the 167 patients had elevations (grades 1 to 4) at both prebaseline and postbaseline in alkaline phosphatase or transaminases, respectively. Only 7.8% (n=13) and 3.0% (n=5) had grade 3 or 4 elevations in alkaline phosphatase or transaminases.

 In the 596 patients treated with XELODA as first-line therapy for metastatic colorectal cancer, the incidence of grade 3 or 4 hyperbilirubinemia was similar to the overall clinical trial safety database of XELODA monotherapy. The median time to onset for grade 3 or 4 hyperbilirubinemia in the colorectal cancer population was 64 days and median total bilirubin increased from 8 um/L at baseline to 13 um/L during treatment with XELODA. Of the 136 colorectal cancer patients with grade 3 or 4 hyperbilirubinemia, 49 patients had grade 3 or 4 hyperbilirubinemia as their last measured value, of which 46 had liver metastases at baseline.

 In 251 patients with metastatic breast cancer who received a combination of XELODA and docetaxel, grade 3 (1.5 to 3 * ULN) hyperbilirubinemia occurred in 7% (n=17) and grade 4 (&gt;3 * ULN) hyperbilirubinemia occurred in 2% (n=5).

 If drug-related grade 3 to 4 elevations in bilirubin occur, administration of XELODA should be immediately interrupted until the hyperbilirubinemia decreases to &lt;=3.0 * ULN [  see recommended dose modifications under   Dosage and Administration (2.3)  ]  .

    5.9 Hematologic

  In 875 patients with either metastatic breast or colorectal cancer who received a dose of 1250 mg/m  2  administered twice daily as monotherapy for 2 weeks followed by a 1-week rest period, 3.2%, 1.7%, and 2.4% of patients had grade 3 or 4 neutropenia, thrombocytopenia or decreases in hemoglobin, respectively. In 251 patients with metastatic breast cancer who received a dose of XELODA in combination with docetaxel, 68% had grade 3 or 4 neutropenia, 2.8% had grade 3 or 4 thrombocytopenia, and 9.6% had grade 3 or 4 anemia.

 Patients with baseline neutrophil counts of &lt;1.5 * 10  9  /L and/or thrombocyte counts of &lt;100 * 10  9  /L should not be treated with XELODA. If unscheduled laboratory assessments during a treatment cycle show grade 3 or 4 hematologic toxicity, treatment with XELODA should be interrupted.

    5.10 Geriatric Patients

  Patients &gt;=80 years old may experience a greater incidence of grade 3 or 4 adverse reactions. In 875 patients with either metastatic breast or colorectal cancer who received XELODA monotherapy, 62% of the 21 patients &gt;=80 years of age treated with XELODA experienced a treatment-related grade 3 or 4 adverse event: diarrhea in 6 (28.6%), nausea in 3 (14.3%), hand-and-foot syndrome in 3 (14.3%), and vomiting in 2 (9.5%) patients. Among the 10 patients 70 years of age and greater (no patients were &gt;80 years of age) treated with XELODA in combination with docetaxel, 30% (3 out of 10) of patients experienced grade 3 or 4 diarrhea and stomatitis, and 40% (4 out of 10) experienced grade 3 hand-and-foot syndrome.

 Among the 67 patients &gt;=60 years of age receiving XELODA in combination with docetaxel, the incidence of grade 3 or 4 treatment-related adverse reactions, treatment-related serious adverse reactions, withdrawals due to adverse reactions, treatment discontinuations due to adverse reactions and treatment discontinuations within the first two treatment cycles was higher than in the &lt;60 years of age patient group.

 In 995 patients receiving XELODA as adjuvant therapy for Dukes' C colon cancer after resection of the primary tumor, 41% of the 398 patients &gt;=65 years of age treated with XELODA experienced a treatment-related grade 3 or 4 adverse event: hand-and-foot syndrome in 75 (18.8%), diarrhea in 52 (13.1%), stomatitis in 12 (3.0%), neutropenia/granulocytopenia in 11 (2.8%), vomiting in 6 (1.5%), and nausea in 5 (1.3%) patients. In patients &gt;=65 years of age (all randomized population; capecitabine 188 patients, 5-FU/LV 208 patients) treated for Dukes' C colon cancer after resection of the primary tumor, the hazard ratios for disease-free survival and overall survival for XELODA compared to 5-FU/LV were 1.01 (95% C.I. 0.80 - 1.27) and 1.04 (95% C.I. 0.79 - 1.37), respectively.

    5.11 Hepatic Insufficiency

  Patients with mild to moderate hepatic dysfunction due to liver metastases should be carefully monitored when XELODA is administered. The effect of severe hepatic dysfunction on the disposition of XELODA is not known [see  Use in Specific Populations (8.6)  and  Clinical Pharmacology (12.3)  ]  .

    5.12 Combination With Other Drugs

  Use of XELODA in combination with irinotecan has not been adequately studied.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="2" />
    <IgnoredRegion len="26" name="heading" section="S3" start="3" />
    <IgnoredRegion len="2167" name="excerpt" section="S3" start="33" />
    <IgnoredRegion len="40" name="heading" section="S2" start="61" />
    <IgnoredRegion len="388" name="excerpt" section="S1" start="292" />
    <IgnoredRegion len="25" name="heading" section="S1" start="684" />
    <IgnoredRegion len="706" name="excerpt" section="S2" start="1292" />
    <IgnoredRegion len="16" name="heading" section="S3" start="2207" />
    <IgnoredRegion len="12" name="heading" section="S3" start="2547" />
    <IgnoredRegion len="18" name="heading" section="S3" start="3670" />
    <IgnoredRegion len="46" name="heading" section="S3" start="4001" />
    <IgnoredRegion len="33" name="heading" section="S3" start="5071" />
    <IgnoredRegion len="25" name="heading" section="S3" start="6428" />
    <IgnoredRegion len="43" name="heading" section="S3" start="7314" />
    <IgnoredRegion len="32" name="heading" section="S1" start="7666" />
    <IgnoredRegion len="22" name="heading" section="S3" start="9071" />
    <IgnoredRegion len="15" name="heading" section="S3" start="11436" />
    <IgnoredRegion len="23" name="heading" section="S3" start="12279" />
    <IgnoredRegion len="26" name="heading" section="S3" start="14222" />
    <IgnoredRegion len="33" name="heading" section="S3" start="14555" />
    <IgnoredRegion len="17" name="heading" section="S1" start="15921" />
    <IgnoredRegion len="57" name="heading" section="S1" start="32819" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M1" len="21" reason="indication" section="S1" start="826" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colon cancer Duke's C" meddra_llt_id="10009949" meddra_pt="Colon cancer stage III" meddra_pt_id="10009955" />
    </Mention>
    <Mention id="M16" len="6" reason="general_term" section="S1" start="1505" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M17" len="24" reason="general_term" section="S1" start="1707" type="NonOSE_AE">
      <Normalization meddra_llt="Laboratory test abnormal" meddra_llt_id="10023547" meddra_pt="Laboratory test abnormal" meddra_pt_id="10023547" />
    </Mention>
    <Mention id="M2" len="21" reason="indication" section="S1" start="1802" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colon cancer Duke's C" meddra_llt_id="10009949" meddra_pt="Colon cancer stage III" meddra_pt_id="10009955" />
    </Mention>
    <Mention id="M8" len="26" reason="general_term" section="S1" start="2363" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M90" len="8" reason="from_drug_use" section="S1" start="2476" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M91" len="6" reason="from_drug_use" section="S1" start="2589" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M92" len="10" reason="from_drug_use" section="S1" start="2702" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis" meddra_llt_id="10042128" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Mention>
    <Mention id="M93" len="8" reason="from_drug_use" section="S1" start="2815" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M94" len="14" reason="from_drug_use" section="S1" start="2928" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M95" len="12" reason="from_drug_use" section="S1" start="3041" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M96" len="20" reason="from_drug_use" section="S1" start="3154" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M97" len="9" reason="from_drug_use" section="S1" start="3267" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M9" len="38" reason="general_term" section="S1" start="3380" type="NonOSE_AE">
      <Normalization meddra_llt="Other disorders of skin and subcutaneous tissue" meddra_llt_id="10032001" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M98" len="22" reason="from_drug_use" section="S1" start="3503" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M99" len="8" reason="from_drug_use" section="S1" start="3616" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alopecia" meddra_llt_id="10001760" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M100" len="4" reason="from_drug_use" section="S1" start="3729" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M101" len="8" reason="from_drug_use" section="S1" start="3842" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythema" meddra_llt_id="10015150" meddra_pt="Erythema" meddra_pt_id="10015150" />
    </Mention>
    <Mention id="M10" len="52" reason="general_term" section="S1" start="3955" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M102" len="7" reason="from_drug_use" section="S1" start="4092" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M103" len="7" reason="from_drug_use" section="S1" start="4205" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pyrexia" meddra_llt_id="10037660" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M104" len="8" reason="from_drug_use" section="S1" start="4318" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M105" len="8" reason="from_drug_use" section="S1" start="4431" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M11" len="24" reason="general_term" section="S1" start="4544" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M106" len="9" reason="from_drug_use" section="S1" start="4657" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M107" len="8" reason="from_drug_use" section="S1" start="4770" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M108" len="9" reason="from_drug_use" section="S1" start="4883" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysgeusia" meddra_llt_id="10013911" meddra_pt="Dysgeusia" meddra_pt_id="10013911" />
    </Mention>
    <Mention id="M12" len="34" reason="general_term" section="S1" start="4996" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified disorder of metabolism" meddra_llt_id="10045811" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M109" len="8" reason="from_drug_use" section="S1" start="5115" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M13" len="13" reason="general_term" section="S1" start="5228" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M110" len="14" reason="from_drug_use" section="S1" start="5341" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Conjunctivitis" meddra_llt_id="10010741" meddra_pt="Conjunctivitis" meddra_pt_id="10010741" />
    </Mention>
    <Mention id="M14" len="36" reason="general_term" section="S1" start="5454" type="NonOSE_AE">
      <Normalization meddra_llt="Blood disorder" meddra_llt_id="10061590" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M111" len="11" reason="from_drug_use" section="S1" start="5575" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M15" len="46" reason="general_term" section="S1" start="5688" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M112" len="9" reason="from_drug_use" section="S1" start="5819" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epistaxis" meddra_llt_id="10015090" meddra_pt="Epistaxis" meddra_pt_id="10015090" />
    </Mention>
    <Mention id="M113" len="20" reason="from_drug_use" section="S1" start="6248" type="OSE_Labeled_AE">
      <Normalization meddra_llt="SGPT increased" meddra_llt_id="10040526" meddra_pt="Alanine aminotransferase increased" meddra_pt_id="10001551" />
    </Mention>
    <Mention id="M114" len="17" reason="from_drug_use" section="S1" start="6357" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Calcium increased" meddra_llt_id="10006963" meddra_pt="Blood calcium increased" meddra_pt_id="10005396" />
    </Mention>
    <Mention id="M115" len="17" reason="from_drug_use" section="S1" start="6466" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Calcium decreased" meddra_llt_id="10006954" meddra_pt="Blood calcium decreased" meddra_pt_id="10005395" />
    </Mention>
    <Mention id="M116" len="20" reason="from_drug_use" section="S1" start="6575" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemoglobin decreased" meddra_llt_id="10019483" meddra_pt="Haemoglobin decreased" meddra_pt_id="10018884" />
    </Mention>
    <Mention id="M323" len="21" reason="from_drug_use" section="S1" start="6684" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lymphocyte count decreased" meddra_llt_id="10025256" meddra_pt="Lymphocyte count decreased" meddra_pt_id="10025256" />
    </Mention>
    <Mention id="M324" len="21" reason="from_drug_use" section="S1" start="6793" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutrophil count decreased" meddra_llt_id="10029366" meddra_pt="Neutrophil count decreased" meddra_pt_id="10029366" />
    </Mention>
    <Mention id="M325" len="30" reason="from_drug_use" section="S1" start="6849" type="OSE_Labeled_AE">
      <Normalization meddra_llt="White blood cell abnormalities" meddra_llt_id="10047935" meddra_pt="White blood cell disorder" meddra_pt_id="10061414" />
    </Mention>
    <Mention id="M117" len="21" reason="from_drug_use" section="S1" start="6991" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutrophil count decreased" meddra_llt_id="10029366" meddra_pt="Neutrophil count decreased" meddra_pt_id="10029366" />
    </Mention>
    <Mention id="M326" len="9,12" reason="from_drug_use" section="S1" start="6991,7013" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Granulocyte count decreased" meddra_llt_id="10018681" meddra_pt="Granulocyte count decreased" meddra_pt_id="10018681" />
    </Mention>
    <Mention id="M118" len="19" reason="from_drug_use" section="S1" start="7100" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Platelets decreased" meddra_llt_id="10035545" meddra_pt="Platelet count decreased" meddra_pt_id="10035528" />
    </Mention>
    <Mention id="M119" len="19" reason="from_drug_use" section="S1" start="7209" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bilirubin increased" meddra_llt_id="10004690" meddra_pt="Blood bilirubin increased" meddra_pt_id="10005364" />
    </Mention>
    <Mention id="M18" len="18" reason="AE_only_as_instruction" section="S1" start="7344" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M19" len="65" reason="AE_only_as_instruction" section="S1" start="7383" type="NonOSE_AE">
      <Normalization meddra_llt="Bilirubin value increased" meddra_llt_id="10004701" meddra_pt="Blood bilirubin increased" meddra_pt_id="10005364" />
    </Mention>
    <Mention id="M20" len="37" reason="AE_only_as_instruction" section="S1" start="7535" type="NonOSE_AE">
      <Normalization meddra_llt="Bilirubin value increased" meddra_llt_id="10004701" meddra_pt="Blood bilirubin increased" meddra_pt_id="10005364" />
    </Mention>
    <Mention id="M3" len="28" reason="indication" section="S1" start="7843" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer metastatic" meddra_llt_id="10052358" meddra_pt="Colorectal cancer metastatic" meddra_pt_id="10052358" />
    </Mention>
    <Mention id="M4" len="28" reason="indication" section="S1" start="7902" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer metastatic" meddra_llt_id="10052358" meddra_pt="Colorectal cancer metastatic" meddra_pt_id="10052358" />
    </Mention>
    <Mention id="M21" len="6" reason="general_term" section="S1" start="8550" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M89" len="2" reason="general_term" section="S1" start="9357" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M120" len="8" reason="from_drug_use" section="S1" start="9474" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M121" len="6" reason="from_drug_use" section="S1" start="9591" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M122" len="8" reason="from_drug_use" section="S1" start="9708" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M123" len="10" reason="from_drug_use" section="S1" start="9825" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis" meddra_llt_id="10042128" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Mention>
    <Mention id="M124" len="14" reason="from_drug_use" section="S1" start="9942" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M125" len="34" reason="from_drug_use" section="S1" start="10059" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal motility disorder" meddra_llt_id="10061173" meddra_pt="Gastrointestinal motility disorder" meddra_pt_id="10061173" />
    </Mention>
    <Mention id="M126" len="12" reason="from_drug_use" section="S1" start="10176" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M127" len="15" reason="from_drug_use" section="S1" start="10293" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oral discomfort" meddra_llt_id="10030973" meddra_pt="Oral discomfort" meddra_pt_id="10030973" />
    </Mention>
    <Mention id="M128" len="31" reason="from_drug_use" section="S1" start="10410" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal inflammation" meddra_llt_id="10064147" meddra_pt="Gastrointestinal inflammation" meddra_pt_id="10064147" />
    </Mention>
    <Mention id="M129" len="27" reason="from_drug_use" section="S1" start="10527" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemorrhage gastrointestinal" meddra_llt_id="10019543" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M130" len="5" reason="from_drug_use" section="S1" start="10644" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ileus" meddra_llt_id="10021328" meddra_pt="Ileus" meddra_pt_id="10021328" />
    </Mention>
    <Mention id="M22" len="21" reason="general_term" section="S1" start="10761" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M131" len="22" reason="from_drug_use" section="S1" start="10878" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M132" len="10" reason="from_drug_use" section="S1" start="10995" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dermatitis" meddra_llt_id="10012431" meddra_pt="Dermatitis" meddra_pt_id="10012431" />
    </Mention>
    <Mention id="M133" len="18" reason="from_drug_use" section="S1" start="11112" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discoloration skin" meddra_llt_id="10013076" meddra_pt="Skin discolouration" meddra_pt_id="10040829" />
    </Mention>
    <Mention id="M134" len="8" reason="from_drug_use" section="S1" start="11229" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alopecia" meddra_llt_id="10001760" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M23" len="7" reason="general_term" section="S1" start="11346" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M135" len="7" reason="from_drug_use" section="S1" start="11463" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M327" len="8" reason="from_drug_use" section="S1" start="11471" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weakness" meddra_llt_id="10047862" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M136" len="7" reason="from_drug_use" section="S1" start="11580" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pyrexia" meddra_llt_id="10037660" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M137" len="5" reason="from_drug_use" section="S1" start="11697" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M138" len="4" reason="from_drug_use" section="S1" start="11814" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M139" len="10" reason="from_drug_use" section="S1" start="11931" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M24" len="12" reason="general_term" section="S1" start="12048" type="NonOSE_AE">
      <Normalization meddra_llt="Neurological complication" meddra_llt_id="10029296" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M328" len="29" reason="from_drug_use" section="S1" start="12165" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sensory peripheral neuropathy" meddra_llt_id="10040039" meddra_pt="Peripheral sensory neuropathy" meddra_pt_id="10034620" />
    </Mention>
    <Mention id="M140" len="8" reason="from_drug_use" section="S1" start="12282" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M141" len="9" reason="from_drug_use" section="S1" start="12399" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M25" len="7" reason="negation" section="S1" start="12426" type="NonOSE_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M142" len="8" reason="from_drug_use" section="S1" start="12516" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M143" len="17" reason="from_drug_use" section="S1" start="12633" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Taste disturbance" meddra_llt_id="10043132" meddra_pt="Dysgeusia" meddra_pt_id="10013911" />
    </Mention>
    <Mention id="M26" len="10" reason="general_term" section="S1" start="12750" type="NonOSE_AE">
      <Normalization meddra_llt="Glucose metabolism abnormal" meddra_llt_id="10058106" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M329" len="18" reason="from_drug_use" section="S1" start="12867" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M144" len="11" reason="from_drug_use" section="S1" start="12984" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M27" len="3" reason="general_term" section="S1" start="13101" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M330" len="14" reason="from_drug_use" section="S1" start="13218" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritation eye" meddra_llt_id="10023013" meddra_pt="Eye irritation" meddra_pt_id="10015946" />
    </Mention>
    <Mention id="M145" len="15" reason="from_drug_use" section="S1" start="13335" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision abnormal" meddra_llt_id="10047508" meddra_pt="Visual impairment" meddra_pt_id="10047571" />
    </Mention>
    <Mention id="M28" len="11" reason="general_term" section="S1" start="13452" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M146" len="7" reason="from_drug_use" section="S1" start="13569" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M147" len="5" reason="from_drug_use" section="S1" start="13686" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cough" meddra_llt_id="10011224" meddra_pt="Cough" meddra_pt_id="10011224" />
    </Mention>
    <Mention id="M331" len="19" reason="from_drug_use" section="S1" start="13803" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngeal disorder" meddra_llt_id="10067353" meddra_pt="Pharyngeal disorder" meddra_pt_id="10067353" />
    </Mention>
    <Mention id="M148" len="9" reason="from_drug_use" section="S1" start="13920" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epistaxis" meddra_llt_id="10015090" meddra_pt="Epistaxis" meddra_pt_id="10015090" />
    </Mention>
    <Mention id="M149" len="11" reason="from_drug_use" section="S1" start="14037" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sore throat" meddra_llt_id="10041367" meddra_pt="Oropharyngeal pain" meddra_pt_id="10068319" />
    </Mention>
    <Mention id="M29" len="15" reason="general_term" section="S1" start="14154" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M332" len="9" reason="from_drug_use" section="S1" start="14271" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M150" len="10" reason="from_drug_use" section="S1" start="14388" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M30" len="8" reason="general_term" section="S1" start="14505" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M151" len="17" reason="from_drug_use" section="S1" start="14622" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis venous" meddra_llt_id="10043640" meddra_pt="Venous thrombosis" meddra_pt_id="10047249" />
    </Mention>
    <Mention id="M31" len="11" reason="general_term" section="S1" start="14739" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M152" len="15" reason="from_drug_use" section="S1" start="14856" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mood alteration NOS" meddra_llt_id="10027937" meddra_pt="Mood altered" meddra_pt_id="10027940" />
    </Mention>
    <Mention id="M153" len="10" reason="from_drug_use" section="S1" start="14973" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M32" len="10" reason="general_term" section="S1" start="15090" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M333" len="122" reason="from_drug_use" section="S1" start="15090" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection viral" meddra_llt_id="10021876" meddra_pt="Viral infection" meddra_pt_id="10047461" />
      <Normalization meddra_pt="Infection reactivation" meddra_pt_id="10070891" />
    </Mention>
    <Mention id="M33" len="19" reason="general_term" section="S1" start="15324" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified diseases of blood and blood-forming organs" meddra_llt_id="10045763" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M154" len="6" reason="from_drug_use" section="S1" start="15441" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anemia" meddra_llt_id="10002272" meddra_pt="Anaemia" meddra_pt_id="10002034" />
    </Mention>
    <Mention id="M155" len="11" reason="from_drug_use" section="S1" start="15558" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M34" len="13" reason="general_term" section="S1" start="15675" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatobiliary disease" meddra_llt_id="10062000" meddra_pt="Hepatobiliary disease" meddra_pt_id="10062000" />
    </Mention>
    <Mention id="M156" len="18" reason="from_drug_use" section="S1" start="15792" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M6" len="24" reason="indication" section="S1" start="16076" type="Not_AE_Candidate">
      <Normalization meddra_llt="Metastatic breast cancer" meddra_llt_id="10027475" meddra_pt="Breast cancer metastatic" meddra_pt_id="10055113" />
    </Mention>
    <Mention id="M35" len="2" reason="general_term" section="S1" start="18199" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M157" len="8" reason="from_drug_use" section="S1" start="18316" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M158" len="10" reason="from_drug_use" section="S1" start="18433" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis" meddra_llt_id="10042128" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Mention>
    <Mention id="M159" len="6" reason="from_drug_use" section="S1" start="18550" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M160" len="8" reason="from_drug_use" section="S1" start="18667" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M334" len="12" reason="from_drug_use" section="S1" start="18784" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M161" len="14" reason="from_drug_use" section="S1" start="18901" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M162" len="9" reason="from_drug_use" section="S1" start="19018" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M163" len="9" reason="from_drug_use" section="S1" start="19135" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M36" len="21" reason="general_term" section="S1" start="19252" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M164" len="22" reason="from_drug_use" section="S1" start="19369" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M165" len="8" reason="from_drug_use" section="S1" start="19486" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alopecia" meddra_llt_id="10001760" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M166" len="13" reason="from_drug_use" section="S1" start="19603" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nail disorder" meddra_llt_id="10028694" meddra_pt="Nail disorder" meddra_pt_id="10028694" />
    </Mention>
    <Mention id="M335" len="10" reason="from_drug_use" section="S1" start="19720" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dermatitis" meddra_llt_id="10012431" meddra_pt="Dermatitis" meddra_pt_id="10012431" />
    </Mention>
    <Mention id="M167" len="17" reason="from_drug_use" section="S1" start="19837" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythematous rash" meddra_llt_id="10015243" meddra_pt="Rash erythematous" meddra_pt_id="10037855" />
    </Mention>
    <Mention id="M168" len="18" reason="from_drug_use" section="S1" start="19954" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nail discoloration" meddra_llt_id="10028691" meddra_pt="Nail discolouration" meddra_pt_id="10028692" />
    </Mention>
    <Mention id="M169" len="11" reason="from_drug_use" section="S1" start="20071" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Onycholysis" meddra_llt_id="10030337" meddra_pt="Onycholysis" meddra_pt_id="10030337" />
    </Mention>
    <Mention id="M170" len="8" reason="from_drug_use" section="S1" start="20188" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M37" len="7" reason="general_term" section="S1" start="20305" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M171" len="7" reason="from_drug_use" section="S1" start="20422" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pyrexia" meddra_llt_id="10037660" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M172" len="8" reason="from_drug_use" section="S1" start="20539" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M173" len="7" reason="from_drug_use" section="S1" start="20656" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M174" len="8" reason="from_drug_use" section="S1" start="20773" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weakness" meddra_llt_id="10047862" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M336" len="12" reason="from_drug_use" section="S1" start="20890" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain in limb" meddra_llt_id="10033447" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M175" len="8" reason="from_drug_use" section="S1" start="21007" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M176" len="4" reason="from_drug_use" section="S1" start="21124" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M177" len="23" reason="from_drug_use" section="S1" start="21241" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Non-cardiac chest pain" meddra_llt_id="10062501" meddra_pt="Non-cardiac chest pain" meddra_pt_id="10062501" />
    </Mention>
    <Mention id="M178" len="22" reason="from_drug_use" section="S1" start="21358" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Influenza like illness" meddra_llt_id="10022004" meddra_pt="Influenza like illness" meddra_pt_id="10022004" />
    </Mention>
    <Mention id="M38" len="12" reason="general_term" section="S1" start="21475" type="NonOSE_AE">
      <Normalization meddra_llt="Neurological complication" meddra_llt_id="10029296" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M337" len="17" reason="from_drug_use" section="S1" start="21592" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Taste disturbance" meddra_llt_id="10043132" meddra_pt="Dysgeusia" meddra_pt_id="10013911" />
    </Mention>
    <Mention id="M338" len="8" reason="from_drug_use" section="S1" start="21709" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M179" len="11" reason="from_drug_use" section="S1" start="21826" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M180" len="9" reason="from_drug_use" section="S1" start="21943" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M181" len="8" reason="from_drug_use" section="S1" start="22060" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M182" len="21" reason="from_drug_use" section="S1" start="22177" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M183" len="13" reason="from_drug_use" section="S1" start="22294" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypoaesthesia" meddra_llt_id="10020937" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" />
    </Mention>
    <Mention id="M39" len="10" reason="general_term" section="S1" start="22411" type="NonOSE_AE">
      <Normalization meddra_llt="Glucose metabolism abnormal" meddra_llt_id="10058106" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M184" len="8" reason="from_drug_use" section="S1" start="22528" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M185" len="18" reason="from_drug_use" section="S1" start="22645" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M186" len="16" reason="from_drug_use" section="S1" start="22762" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M187" len="11" reason="from_drug_use" section="S1" start="22879" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M40" len="3" reason="general_term" section="S1" start="22996" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M188" len="21" reason="from_drug_use" section="S1" start="23113" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lacrimation increased" meddra_llt_id="10023644" meddra_pt="Lacrimation increased" meddra_pt_id="10023644" />
    </Mention>
    <Mention id="M189" len="14" reason="from_drug_use" section="S1" start="23230" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Conjunctivitis" meddra_llt_id="10010741" meddra_pt="Conjunctivitis" meddra_pt_id="10010741" />
    </Mention>
    <Mention id="M190" len="14" reason="from_drug_use" section="S1" start="23347" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritation eye" meddra_llt_id="10023013" meddra_pt="Eye irritation" meddra_pt_id="10015946" />
    </Mention>
    <Mention id="M41" len="15" reason="general_term" section="S1" start="23464" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M191" len="10" reason="from_drug_use" section="S1" start="23581" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M192" len="7" reason="from_drug_use" section="S1" start="23698" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M193" len="9" reason="from_drug_use" section="S1" start="23815" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M194" len="9" reason="from_drug_use" section="S1" start="23932" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain bone" meddra_llt_id="10033384" meddra_pt="Bone pain" meddra_pt_id="10006002" />
    </Mention>
    <Mention id="M42" len="7" reason="general_term" section="S1" start="24049" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M339" len="5" reason="from_drug_use" section="S1" start="24166" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M43" len="5" reason="general_term" section="S1" start="24283" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified diseases of blood and blood-forming organs" meddra_llt_id="10045763" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M195" len="17" reason="from_drug_use" section="S1" start="24400" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenic fever" meddra_llt_id="10051312" meddra_pt="Febrile neutropenia" meddra_pt_id="10016288" />
    </Mention>
    <Mention id="M44" len="11" reason="general_term" section="S1" start="24517" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M340" len="7" reason="from_drug_use" section="S1" start="24634" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M196" len="5" reason="from_drug_use" section="S1" start="24751" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cough" meddra_llt_id="10011224" meddra_pt="Cough" meddra_pt_id="10011224" />
    </Mention>
    <Mention id="M197" len="11" reason="from_drug_use" section="S1" start="24868" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sore throat" meddra_llt_id="10041367" meddra_pt="Oropharyngeal pain" meddra_pt_id="10068319" />
    </Mention>
    <Mention id="M198" len="9" reason="from_drug_use" section="S1" start="24985" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epistaxis" meddra_llt_id="10015090" meddra_pt="Epistaxis" meddra_pt_id="10015090" />
    </Mention>
    <Mention id="M199" len="10" reason="from_drug_use" section="S1" start="25102" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhinorrhea" meddra_llt_id="10039100" meddra_pt="Rhinorrhoea" meddra_pt_id="10039101" />
    </Mention>
    <Mention id="M200" len="16" reason="from_drug_use" section="S1" start="25219" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Effusion pleural" meddra_llt_id="10014313" meddra_pt="Pleural effusion" meddra_pt_id="10035598" />
    </Mention>
    <Mention id="M45" len="9" reason="general_term" section="S1" start="25336" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M341" len="16" reason="from_drug_use" section="S1" start="25453" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oral candidiasis" meddra_llt_id="10030963" meddra_pt="Oral candidiasis" meddra_pt_id="10030963" />
    </Mention>
    <Mention id="M201" len="23" reason="from_drug_use" section="S1" start="25570" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection urinary tract" meddra_llt_id="10021872" meddra_pt="Urinary tract infection" meddra_pt_id="10046571" />
    </Mention>
    <Mention id="M202" len="23" reason="from_drug_use" section="S1" start="25687" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract inflammation" meddra_llt_id="10049590" meddra_pt="Upper respiratory tract inflammation" meddra_pt_id="10049590" />
    </Mention>
    <Mention id="M46" len="8" reason="general_term" section="S1" start="25804" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M203" len="8" reason="from_drug_use" section="S1" start="25921" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flushing" meddra_llt_id="10016825" meddra_pt="Flushing" meddra_pt_id="10016825" />
    </Mention>
    <Mention id="M204" len="11" reason="from_drug_use" section="S1" start="26038" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lymphoedema" meddra_llt_id="10025282" meddra_pt="Lymphoedema" meddra_pt_id="10025282" />
    </Mention>
    <Mention id="M47" len="11" reason="general_term" section="S1" start="26155" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M205" len="10" reason="from_drug_use" section="S1" start="26272" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M48" len="11" reason="general_term" section="S1" start="26873" type="NonOSE_AE">
      <Normalization meddra_llt="Hematologic disorder" meddra_llt_id="10019426" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M206" len="10" reason="from_drug_use" section="S1" start="26990" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M207" len="11" reason="from_drug_use" section="S1" start="27107" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M208" len="16" reason="from_drug_use" section="S1" start="27119" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Granulocytopenia" meddra_llt_id="10018687" meddra_pt="Granulocytopenia" meddra_pt_id="10018687" />
    </Mention>
    <Mention id="M209" len="16" reason="from_drug_use" section="S1" start="27224" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M210" len="6" reason="from_drug_use" section="S1" start="27341" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anemia" meddra_llt_id="10002272" meddra_pt="Anaemia" meddra_pt_id="10002034" />
    </Mention>
    <Mention id="M211" len="15" reason="from_drug_use" section="S1" start="27458" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lymphocytopenia" meddra_llt_id="10025278" meddra_pt="Lymphopenia" meddra_pt_id="10025327" />
    </Mention>
    <Mention id="M49" len="13" reason="general_term" section="S1" start="27575" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatobiliary disease" meddra_llt_id="10062000" meddra_pt="Hepatobiliary disease" meddra_pt_id="10062000" />
    </Mention>
    <Mention id="M212" len="18" reason="from_drug_use" section="S1" start="27692" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M7" len="22" reason="indication" section="S1" start="27887" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer stage IV" meddra_llt_id="10006202" meddra_pt="Breast cancer stage IV" meddra_pt_id="10006202" />
    </Mention>
    <Mention id="M5" len="7" reason="preexisting_condition_or_risk_factor" section="S1" start="28176" type="Not_AE_Candidate">
      <Normalization meddra_llt="Illness" meddra_llt_id="10080284" meddra_pt="Ill-defined disorder" meddra_pt_id="10061520" />
    </Mention>
    <Mention id="M50" len="2" reason="general_term" section="S1" start="28703" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M213" len="8" reason="from_drug_use" section="S1" start="28812" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M214" len="6" reason="from_drug_use" section="S1" start="28923" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M215" len="8" reason="from_drug_use" section="S1" start="29034" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M216" len="10" reason="from_drug_use" section="S1" start="29145" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis" meddra_llt_id="10042128" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Mention>
    <Mention id="M217" len="14" reason="from_drug_use" section="S1" start="29256" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M218" len="12" reason="from_drug_use" section="S1" start="29367" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M219" len="9" reason="from_drug_use" section="S1" start="29478" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M51" len="21" reason="general_term" section="S1" start="29591" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M220" len="22" reason="from_drug_use" section="S1" start="29700" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M221" len="10" reason="from_drug_use" section="S1" start="29811" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dermatitis" meddra_llt_id="10012431" meddra_pt="Dermatitis" meddra_pt_id="10012431" />
    </Mention>
    <Mention id="M222" len="13" reason="from_drug_use" section="S1" start="29922" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nail disorder" meddra_llt_id="10028694" meddra_pt="Nail disorder" meddra_pt_id="10028694" />
    </Mention>
    <Mention id="M52" len="7" reason="general_term" section="S1" start="30035" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M223" len="7" reason="from_drug_use" section="S1" start="30144" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M224" len="7" reason="from_drug_use" section="S1" start="30255" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pyrexia" meddra_llt_id="10037660" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M342" len="12" reason="from_drug_use" section="S1" start="30366" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain in limb" meddra_llt_id="10033447" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M53" len="12" reason="general_term" section="S1" start="30479" type="NonOSE_AE">
      <Normalization meddra_llt="Neurological complication" meddra_llt_id="10029296" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M343" len="11" reason="from_drug_use" section="S1" start="30588" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M225" len="8" reason="from_drug_use" section="S1" start="30699" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M344" len="9" reason="from_drug_use" section="S1" start="30810" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M226" len="8" reason="from_drug_use" section="S1" start="30921" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M54" len="10" reason="general_term" section="S1" start="31034" type="NonOSE_AE">
      <Normalization meddra_llt="Glucose metabolism abnormal" meddra_llt_id="10058106" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M227" len="8" reason="from_drug_use" section="S1" start="31143" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M228" len="11" reason="from_drug_use" section="S1" start="31254" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M55" len="3" reason="general_term" section="S1" start="31367" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M345" len="14" reason="from_drug_use" section="S1" start="31476" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritation eye" meddra_llt_id="10023013" meddra_pt="Eye irritation" meddra_pt_id="10015946" />
    </Mention>
    <Mention id="M56" len="15" reason="general_term" section="S1" start="31589" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M229" len="7" reason="from_drug_use" section="S1" start="31698" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M57" len="7" reason="general_term" section="S1" start="31811" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M346" len="5" reason="from_drug_use" section="S1" start="31920" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M58" len="5" reason="general_term" section="S1" start="32033" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified diseases of blood and blood-forming organs" meddra_llt_id="10045763" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M230" len="11" reason="from_drug_use" section="S1" start="32142" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M231" len="16" reason="from_drug_use" section="S1" start="32253" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M232" len="6" reason="from_drug_use" section="S1" start="32364" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anemia" meddra_llt_id="10002272" meddra_pt="Anaemia" meddra_pt_id="10002034" />
    </Mention>
    <Mention id="M233" len="11" reason="from_drug_use" section="S1" start="32475" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lymphopenia" meddra_llt_id="10025327" meddra_pt="Lymphopenia" meddra_pt_id="10025327" />
    </Mention>
    <Mention id="M59" len="13" reason="general_term" section="S1" start="32588" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatobiliary disease" meddra_llt_id="10062000" meddra_pt="Hepatobiliary disease" meddra_pt_id="10062000" />
    </Mention>
    <Mention id="M234" len="18" reason="from_drug_use" section="S1" start="32697" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M60" len="16" reason="general_term" section="S1" start="33282" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M235" len="20" reason="from_drug_use" section="S1" start="33303" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abdominal distension" meddra_llt_id="10000060" meddra_pt="Abdominal distension" meddra_pt_id="10000060" />
    </Mention>
    <Mention id="M236" len="9" reason="from_drug_use" section="S1" start="33325" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysphagia" meddra_llt_id="10013950" meddra_pt="Dysphagia" meddra_pt_id="10013950" />
    </Mention>
    <Mention id="M237" len="10" reason="from_drug_use" section="S1" start="33336" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Proctalgia" meddra_llt_id="10036772" meddra_pt="Proctalgia" meddra_pt_id="10036772" />
    </Mention>
    <Mention id="M238" len="7" reason="from_drug_use" section="S1" start="33348" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ascites" meddra_llt_id="10003445" meddra_pt="Ascites" meddra_pt_id="10003445" />
    </Mention>
    <Mention id="M239" len="13" reason="from_drug_use" section="S1" start="33364" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastric ulcer" meddra_llt_id="10017822" meddra_pt="Gastric ulcer" meddra_pt_id="10017822" />
    </Mention>
    <Mention id="M240" len="5" reason="from_drug_use" section="S1" start="33386" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ileus" meddra_llt_id="10021328" meddra_pt="Ileus" meddra_pt_id="10021328" />
    </Mention>
    <Mention id="M241" len="27" reason="from_drug_use" section="S1" start="33400" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic dilatation of intestine" meddra_llt_id="10044145" meddra_pt="Toxic dilatation of intestine" meddra_pt_id="10044145" />
    </Mention>
    <Mention id="M242" len="15" reason="from_drug_use" section="S1" start="33429" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastroenteritis" meddra_llt_id="10017888" meddra_pt="Gastroenteritis" meddra_pt_id="10017888" />
    </Mention>
    <Mention id="M61" len="15" reason="general_term" section="S1" start="33458" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M243" len="13" reason="from_drug_use" section="S1" start="33479" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nail disorder" meddra_llt_id="10028694" meddra_pt="Nail disorder" meddra_pt_id="10028694" />
    </Mention>
    <Mention id="M244" len="18" reason="from_drug_use" section="S1" start="33501" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sweating increased" meddra_llt_id="10042667" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M245" len="25" reason="from_drug_use" section="S1" start="33528" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Photosensitivity reaction" meddra_llt_id="10034972" meddra_pt="Photosensitivity reaction" meddra_pt_id="10034972" />
    </Mention>
    <Mention id="M246" len="15" reason="from_drug_use" section="S1" start="33562" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin ulceration" meddra_llt_id="10040947" meddra_pt="Skin ulcer" meddra_pt_id="10040943" />
    </Mention>
    <Mention id="M247" len="8" reason="from_drug_use" section="S1" start="33579" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M248" len="25" reason="from_drug_use" section="S1" start="33589" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Radiation recall syndrome" meddra_llt_id="10037768" meddra_pt="Recall phenomenon" meddra_pt_id="10060856" />
    </Mention>
    <Mention id="M62" len="7" reason="general_term" section="S1" start="33628" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M249" len="10" reason="from_drug_use" section="S1" start="33648" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M250" len="22" reason="from_drug_use" section="S1" start="33667" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Influenza like illness" meddra_llt_id="10022004" meddra_pt="Influenza like illness" meddra_pt_id="10022004" />
    </Mention>
    <Mention id="M347" len="11" reason="from_drug_use" section="S1" start="33691" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hot flush" meddra_llt_id="10060800" meddra_pt="Hot flush" meddra_pt_id="10060800" />
    </Mention>
    <Mention id="M348" len="4" reason="from_drug_use" section="S1" start="33704" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M251" len="10" reason="from_drug_use" section="S1" start="33717" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hoarseness" meddra_llt_id="10020201" meddra_pt="Dysphonia" meddra_pt_id="10013952" />
    </Mention>
    <Mention id="M252" len="12" reason="from_drug_use" section="S1" start="33729" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M253" len="21" reason="from_drug_use" section="S1" start="33743" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Difficulty in walking" meddra_llt_id="10012794" meddra_pt="Gait disturbance" meddra_pt_id="10017577" />
    </Mention>
    <Mention id="M254" len="6" reason="from_drug_use" section="S1" start="33766" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thirst" meddra_llt_id="10043458" meddra_pt="Thirst" meddra_pt_id="10043458" />
    </Mention>
    <Mention id="M255" len="10" reason="from_drug_use" section="S1" start="33774" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Chest wall mass" meddra_llt_id="10063004" meddra_pt="Chest wall mass" meddra_pt_id="10063004" />
    </Mention>
    <Mention id="M256" len="8" reason="from_drug_use" section="S1" start="33786" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Collapse" meddra_llt_id="10009907" meddra_pt="Circulatory collapse" meddra_pt_id="10009192" />
    </Mention>
    <Mention id="M349" len="8" reason="from_drug_use" section="S1" start="33796" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fibrosis" meddra_llt_id="10016642" meddra_pt="Fibrosis" meddra_pt_id="10016642" />
    </Mention>
    <Mention id="M257" len="10" reason="from_drug_use" section="S1" start="33813" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemorrhage" meddra_llt_id="10019524" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M258" len="5" reason="from_drug_use" section="S1" start="33825" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M350" len="8" reason="from_drug_use" section="S1" start="33832" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M63" len="12" reason="general_term" section="S1" start="33847" type="NonOSE_AE">
      <Normalization meddra_llt="Neurological complication" meddra_llt_id="10029296" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M259" len="8" reason="from_drug_use" section="S1" start="33867" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M260" len="6" reason="from_drug_use" section="S1" start="33877" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ataxia" meddra_llt_id="10003591" meddra_pt="Ataxia" meddra_pt_id="10003591" />
    </Mention>
    <Mention id="M261" len="6" reason="from_drug_use" section="S1" start="33892" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M262" len="9" reason="from_drug_use" section="S1" start="33900" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysphasia" meddra_llt_id="10013951" meddra_pt="Aphasia" meddra_pt_id="10002948" />
    </Mention>
    <Mention id="M263" len="14" reason="from_drug_use" section="S1" start="33911" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Encephalopathy" meddra_llt_id="10014625" meddra_pt="Encephalopathy" meddra_pt_id="10014625" />
    </Mention>
    <Mention id="M264" len="21" reason="from_drug_use" section="S1" start="33934" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coordination abnormal" meddra_llt_id="10010947" meddra_pt="Coordination abnormal" meddra_pt_id="10010947" />
    </Mention>
    <Mention id="M265" len="10" reason="from_drug_use" section="S1" start="33957" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysarthria" meddra_llt_id="10013887" meddra_pt="Dysarthria" meddra_pt_id="10013887" />
    </Mention>
    <Mention id="M266" len="21" reason="from_drug_use" section="S1" start="33969" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Consciousness loss of" meddra_llt_id="10010772" meddra_pt="Loss of consciousness" meddra_pt_id="10024855" />
    </Mention>
    <Mention id="M351" len="16" reason="from_drug_use" section="S1" start="33999" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Balance impaired NOS" meddra_llt_id="10004071" meddra_pt="Balance disorder" meddra_pt_id="10049848" />
    </Mention>
    <Mention id="M64" len="10" reason="general_term" section="S1" start="34022" type="NonOSE_AE">
      <Normalization meddra_llt="Glucose metabolism abnormal" meddra_llt_id="10058106" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M267" len="16" reason="from_drug_use" section="S1" start="34042" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increased" meddra_llt_id="10047899" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M268" len="8" reason="from_drug_use" section="S1" start="34060" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cachexia" meddra_llt_id="10006895" meddra_pt="Cachexia" meddra_pt_id="10006895" />
    </Mention>
    <Mention id="M269" len="20" reason="from_drug_use" section="S1" start="34077" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertriglyceridemia" meddra_llt_id="10020870" meddra_pt="Hypertriglyceridaemia" meddra_pt_id="10020869" />
    </Mention>
    <Mention id="M270" len="11" reason="from_drug_use" section="S1" start="34106" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypokalemia" meddra_llt_id="10021018" meddra_pt="Hypokalaemia" meddra_pt_id="10021015" />
      <Normalization meddra_pt="Blood potassium decreased" meddra_pt_id="10005724" />
    </Mention>
    <Mention id="M271" len="14" reason="from_drug_use" section="S1" start="34119" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypomagnesemia" meddra_llt_id="10021028" meddra_pt="Hypomagnesaemia" meddra_pt_id="10021027" />
    </Mention>
    <Mention id="M65" len="3" reason="general_term" section="S1" start="34140" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M272" len="14" reason="from_drug_use" section="S1" start="34160" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Conjunctivitis" meddra_llt_id="10010741" meddra_pt="Conjunctivitis" meddra_pt_id="10010741" />
    </Mention>
    <Mention id="M66" len="11" reason="general_term" section="S1" start="34247" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M273" len="5" reason="from_drug_use" section="S1" start="34267" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cough" meddra_llt_id="10011224" meddra_pt="Cough" meddra_pt_id="10011224" />
    </Mention>
    <Mention id="M274" len="9" reason="from_drug_use" section="S1" start="34281" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epistaxis" meddra_llt_id="10015090" meddra_pt="Epistaxis" meddra_pt_id="10015090" />
    </Mention>
    <Mention id="M275" len="6" reason="from_drug_use" section="S1" start="34299" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthma" meddra_llt_id="10003553" meddra_pt="Asthma" meddra_pt_id="10003553" />
    </Mention>
    <Mention id="M276" len="10" reason="from_drug_use" section="S1" start="34314" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemoptysis" meddra_llt_id="10019523" meddra_pt="Haemoptysis" meddra_pt_id="10018964" />
    </Mention>
    <Mention id="M277" len="20" reason="from_drug_use" section="S1" start="34326" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Distress respiratory" meddra_llt_id="10013492" meddra_pt="Respiratory distress" meddra_pt_id="10038687" />
    </Mention>
    <Mention id="M278" len="7" reason="from_drug_use" section="S1" start="34355" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M67" len="7" reason="general_term" section="S1" start="34369" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M279" len="11" reason="from_drug_use" section="S1" start="34389" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M280" len="11" reason="from_drug_use" section="S1" start="34409" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M281" len="19" reason="from_drug_use" section="S1" start="34422" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Atrial fibrillation" meddra_llt_id="10003658" meddra_pt="Atrial fibrillation" meddra_pt_id="10003658" />
    </Mention>
    <Mention id="M282" len="25" reason="from_drug_use" section="S1" start="34443" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrasystoles ventricular" meddra_llt_id="10015864" meddra_pt="Ventricular extrasystoles" meddra_pt_id="10047289" />
    </Mention>
    <Mention id="M283" len="13" reason="from_drug_use" section="S1" start="34470" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrasystoles" meddra_llt_id="10015856" meddra_pt="Extrasystoles" meddra_pt_id="10015856" />
    </Mention>
    <Mention id="M284" len="11" reason="from_drug_use" section="S1" start="34485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocarditis" meddra_llt_id="10028606" meddra_pt="Myocarditis" meddra_pt_id="10028606" />
    </Mention>
    <Mention id="M352" len="20" reason="from_drug_use" section="S1" start="34505" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Effusion pericardial" meddra_llt_id="10014311" meddra_pt="Pericardial effusion" meddra_pt_id="10034474" />
    </Mention>
    <Mention id="M68" len="10" reason="general_term" section="S1" start="34532" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M285" len="10" reason="from_drug_use" section="S1" start="34552" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Laryngitis" meddra_llt_id="10023874" meddra_pt="Laryngitis" meddra_pt_id="10023874" />
    </Mention>
    <Mention id="M286" len="10" reason="from_drug_use" section="S1" start="34571" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchitis" meddra_llt_id="10006451" meddra_pt="Bronchitis" meddra_pt_id="10006451" />
    </Mention>
    <Mention id="M287" len="9" reason="from_drug_use" section="S1" start="34590" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M288" len="16" reason="from_drug_use" section="S1" start="34608" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchopneumonia" meddra_llt_id="10006469" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M289" len="20" reason="from_drug_use" section="S1" start="34633" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Keratoconjunctivitis" meddra_llt_id="10023348" meddra_pt="Keratitis" meddra_pt_id="10023332" />
    </Mention>
    <Mention id="M290" len="6" reason="from_drug_use" section="S1" start="34655" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sepsis" meddra_llt_id="10040047" meddra_pt="Sepsis" meddra_pt_id="10040047" />
    </Mention>
    <Mention id="M291" len="17" reason="from_drug_use" section="S1" start="34670" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection fungal" meddra_llt_id="10021814" meddra_pt="Fungal infection" meddra_pt_id="10017533" />
    </Mention>
    <Mention id="M292" len="11" reason="from_drug_use" section="S1" start="34699" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Candidiasis" meddra_llt_id="10007152" meddra_pt="Candida infection" meddra_pt_id="10074170" />
    </Mention>
    <Mention id="M69" len="15" reason="general_term" section="S1" start="34725" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M293" len="7" reason="from_drug_use" section="S1" start="34745" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M294" len="9" reason="from_drug_use" section="S1" start="34754" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain bone" meddra_llt_id="10033384" meddra_pt="Bone pain" meddra_pt_id="10006002" />
    </Mention>
    <Mention id="M295" len="9" reason="from_drug_use" section="S1" start="34772" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthritis" meddra_llt_id="10003246" meddra_pt="Arthritis" meddra_pt_id="10003246" />
    </Mention>
    <Mention id="M296" len="15" reason="from_drug_use" section="S1" start="34790" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle weakness" meddra_llt_id="10028350" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M70" len="17" reason="general_term" section="S1" start="34832" type="NonOSE_AE">
      <Normalization meddra_llt="Blood disorder" meddra_llt_id="10061590" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M297" len="10" reason="from_drug_use" section="S1" start="34854" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M298" len="20" reason="from_drug_use" section="S1" start="34873" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder coagulation" meddra_llt_id="10013206" meddra_pt="Coagulopathy" meddra_pt_id="10009802" />
    </Mention>
    <Mention id="M299" len="22" reason="from_drug_use" section="S1" start="34902" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bone marrow depression" meddra_llt_id="10005986" meddra_pt="Bone marrow failure" meddra_pt_id="10065553" />
    </Mention>
    <Mention id="M300" len="35" reason="from_drug_use" section="S1" start="34933" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Idiopathic thrombocytopenia" meddra_llt_id="10051057" meddra_pt="Immune thrombocytopenic purpura" meddra_pt_id="10074667" />
    </Mention>
    <Mention id="M301" len="12" reason="from_drug_use" section="S1" start="34977" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pancytopenia" meddra_llt_id="10033661" meddra_pt="Pancytopenia" meddra_pt_id="10033661" />
    </Mention>
    <Mention id="M71" len="8" reason="general_term" section="S1" start="35003" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M302" len="11" reason="from_drug_use" section="S1" start="35023" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M303" len="12" reason="from_drug_use" section="S1" start="35043" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M304" len="11" reason="from_drug_use" section="S1" start="35064" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lymphoedema" meddra_llt_id="10025282" meddra_pt="Lymphoedema" meddra_pt_id="10025282" />
    </Mention>
    <Mention id="M305" len="18" reason="from_drug_use" section="S1" start="35084" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary embolism" meddra_llt_id="10037377" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M306" len="24" reason="from_drug_use" section="S1" start="35111" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Accident cerebrovascular" meddra_llt_id="10000374" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M72" len="11" reason="general_term" section="S1" start="35149" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M307" len="10" reason="from_drug_use" section="S1" start="35169" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M308" len="9" reason="from_drug_use" section="S1" start="35181" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Confusion" meddra_llt_id="10010300" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M73" len="5" reason="general_term" section="S1" start="35256" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder renal" meddra_llt_id="10013263" meddra_pt="Renal disorder" meddra_pt_id="10038428" />
    </Mention>
    <Mention id="M309" len="16" reason="from_drug_use" section="S1" start="35276" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Renal impairment" meddra_llt_id="10062237" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M74" len="3" reason="general_term" section="S1" start="35363" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder ear" meddra_llt_id="10013214" meddra_pt="Ear disorder" meddra_pt_id="10014004" />
    </Mention>
    <Mention id="M310" len="7" reason="from_drug_use" section="S1" start="35383" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M75" len="13" reason="general_term" section="S1" start="35470" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatobiliary disease" meddra_llt_id="10062000" meddra_pt="Hepatobiliary disease" meddra_pt_id="10062000" />
    </Mention>
    <Mention id="M311" len="16" reason="from_drug_use" section="S1" start="35490" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatic fibrosis" meddra_llt_id="10019668" meddra_pt="Hepatic fibrosis" meddra_pt_id="10019668" />
    </Mention>
    <Mention id="M312" len="9" reason="from_drug_use" section="S1" start="35515" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatitis" meddra_llt_id="10019717" meddra_pt="Hepatitis" meddra_pt_id="10019717" />
    </Mention>
    <Mention id="M313" len="21" reason="from_drug_use" section="S1" start="35533" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cholestatic hepatitis" meddra_llt_id="10008639" meddra_pt="Hepatitis cholestatic" meddra_pt_id="10019754" />
    </Mention>
    <Mention id="M314" len="29" reason="from_drug_use" section="S1" start="35563" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abnormal liver function tests" meddra_llt_id="10000158" meddra_pt="Liver function test abnormal" meddra_pt_id="10024690" />
    </Mention>
    <Mention id="M76" len="13" reason="general_term" section="S1" start="35599" type="NonOSE_AE">
      <Normalization meddra_llt="Immune system disorder" meddra_llt_id="10021425" meddra_pt="Immune system disorder" meddra_pt_id="10021425" />
    </Mention>
    <Mention id="M353" len="21" reason="from_drug_use" section="S1" start="35619" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M315" len="15" reason="from_drug_use" section="S1" start="35726" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatic failure" meddra_llt_id="10019663" meddra_pt="Hepatic failure" meddra_pt_id="10019663" />
    </Mention>
    <Mention id="M316" len="22" reason="from_drug_use" section="S1" start="35743" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lacrimal duct obstruction" meddra_llt_id="10023622" meddra_pt="Dacryostenosis acquired" meddra_pt_id="10053990" />
    </Mention>
    <Mention id="M77" len="19" reason="manifestation_or_complication" section="S1" start="35767" type="NonOSE_AE">
      <Normalization meddra_llt="Renal failure acute" meddra_llt_id="10038436" meddra_pt="Acute kidney injury" meddra_pt_id="10069339" />
    </Mention>
    <Mention id="M354" len="11" reason="from_drug_use" section="S1" start="35800" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M78" len="5" reason="general_term" section="S1" start="35822" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M317" len="29" reason="from_drug_use" section="S1" start="35880" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cutaneous lupus erythematosus" meddra_llt_id="10056509" meddra_pt="Cutaneous lupus erythematosus" meddra_pt_id="10056509" />
    </Mention>
    <Mention id="M318" len="17" reason="from_drug_use" section="S1" start="35911" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Corneal disorder" meddra_llt_id="10061453" meddra_pt="Corneal disorder" meddra_pt_id="10061453" />
    </Mention>
    <Mention id="M319" len="9" reason="from_drug_use" section="S1" start="35939" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Keratitis" meddra_llt_id="10023332" meddra_pt="Keratitis" meddra_pt_id="10023332" />
    </Mention>
    <Mention id="M320" len="25" reason="from_drug_use" section="S1" start="35950" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic leukoencephalopathy" meddra_llt_id="10075528" meddra_pt="Toxic leukoencephalopathy" meddra_pt_id="10075528" />
    </Mention>
    <Mention id="M321" len="14" reason="from_drug_use" section="S1" start="35984" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Reaction skin" meddra_llt_id="10037971" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
      <Normalization meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
    </Mention>
    <Mention id="M322" len="24" reason="from_drug_use" section="S1" start="36007" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syndrome Stevens-Johnson" meddra_llt_id="10042849" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Mention>
    <Mention id="M356" len="31" reason="from_drug_use" section="S1" start="36036" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic epidermal necrolysis" meddra_llt_id="10044223" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Mention>
    <Mention id="M355" len="22" reason="from_drug_use" section="S1" start="36137" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M79" len="20" reason="manifestation_or_complication" section="S1" start="36183" type="NonOSE_AE">
      <Normalization meddra_llt="Fingerprint loss" meddra_llt_id="10069686" meddra_pt="Fingerprint loss" meddra_pt_id="10069686" />
    </Mention>
    <Mention id="M80" len="16" reason="general_term" section="S1" start="36336" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M357" len="5" reason="from_drug_use" section="S1" start="36357" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ileus" meddra_llt_id="10021328" meddra_pt="Ileus" meddra_pt_id="10021328" />
    </Mention>
    <Mention id="M358" len="25" reason="from_drug_use" section="S1" start="36371" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Enterocolitis necrotizing" meddra_llt_id="10055642" meddra_pt="Necrotising colitis" meddra_pt_id="10051606" />
    </Mention>
    <Mention id="M359" len="16" reason="from_drug_use" section="S1" start="36405" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Esophageal ulcer" meddra_llt_id="10015451" meddra_pt="Oesophageal ulcer" meddra_pt_id="10030201" />
    </Mention>
    <Mention id="M360" len="20" reason="from_drug_use" section="S1" start="36430" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea hemorrhagic" meddra_llt_id="10060536" meddra_pt="Diarrhoea haemorrhagic" meddra_pt_id="10012741" />
    </Mention>
    <Mention id="M81" len="12" reason="general_term" section="S1" start="36464" type="NonOSE_AE">
      <Normalization meddra_llt="Neurological complication" meddra_llt_id="10029296" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M361" len="6" reason="from_drug_use" section="S1" start="36484" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ataxia" meddra_llt_id="10003591" meddra_pt="Ataxia" meddra_pt_id="10003591" />
    </Mention>
    <Mention id="M362" len="7" reason="from_drug_use" section="S1" start="36499" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M363" len="10" reason="from_drug_use" section="S1" start="36515" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Taste loss" meddra_llt_id="10043134" meddra_pt="Ageusia" meddra_pt_id="10001480" />
    </Mention>
    <Mention id="M364" len="14" reason="from_drug_use" section="S1" start="36534" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Polyneuropathy" meddra_llt_id="10036105" meddra_pt="Polyneuropathy" meddra_pt_id="10036105" />
    </Mention>
    <Mention id="M82" len="7" reason="general_term" section="S1" start="36579" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M365" len="28" reason="from_drug_use" section="S1" start="36599" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia supraventricular" meddra_llt_id="10043084" meddra_pt="Supraventricular tachycardia" meddra_pt_id="10042604" />
    </Mention>
    <Mention id="M83" len="9" reason="general_term" section="S1" start="36686" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M366" len="18" reason="from_drug_use" section="S1" start="36706" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenic sepsis" meddra_llt_id="10049151" meddra_pt="Neutropenic sepsis" meddra_pt_id="10049151" />
    </Mention>
    <Mention id="M367" len="6" reason="from_drug_use" section="S1" start="36733" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sepsis" meddra_llt_id="10040047" meddra_pt="Sepsis" meddra_pt_id="10040047" />
    </Mention>
    <Mention id="M368" len="16" reason="from_drug_use" section="S1" start="36748" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchopneumonia" meddra_llt_id="10006469" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M84" len="17" reason="general_term" section="S1" start="36793" type="NonOSE_AE">
      <Normalization meddra_llt="Blood disorder" meddra_llt_id="10061590" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M369" len="15" reason="from_drug_use" section="S1" start="36815" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agranulocytosis" meddra_llt_id="10001507" meddra_pt="Agranulocytosis" meddra_pt_id="10001507" />
    </Mention>
    <Mention id="M370" len="21" reason="from_drug_use" section="S1" start="36839" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Prothrombin decreased" meddra_llt_id="10037044" meddra_pt="Prothrombin level decreased" meddra_pt_id="10037050" />
    </Mention>
    <Mention id="M85" len="8" reason="general_term" section="S1" start="36902" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M371" len="11" reason="from_drug_use" section="S1" start="36922" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M372" len="16" reason="from_drug_use" section="S1" start="36942" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Phlebitis" meddra_llt_id="10034879" meddra_pt="Phlebitis" meddra_pt_id="10034879" />
    </Mention>
    <Mention id="M373" len="16" reason="from_drug_use" section="S1" start="36963" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombophlebitis" meddra_llt_id="10043570" meddra_pt="Thrombophlebitis" meddra_pt_id="10043570" />
    </Mention>
    <Mention id="M374" len="20" reason="from_drug_use" section="S1" start="36988" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Postural hypotension" meddra_llt_id="10036433" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M86" len="5" reason="general_term" section="S1" start="37022" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder renal" meddra_llt_id="10013263" meddra_pt="Renal disorder" meddra_pt_id="10038428" />
    </Mention>
    <Mention id="M375" len="13" reason="from_drug_use" section="S1" start="37042" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Renal failure" meddra_llt_id="10038435" meddra_pt="Renal failure" meddra_pt_id="10038435" />
    </Mention>
    <Mention id="M87" len="13" reason="general_term" section="S1" start="37129" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatobiliary disease" meddra_llt_id="10062000" meddra_pt="Hepatobiliary disease" meddra_pt_id="10062000" />
    </Mention>
    <Mention id="M376" len="8" reason="from_drug_use" section="S1" start="37149" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Jaundice" meddra_llt_id="10023126" meddra_pt="Jaundice" meddra_pt_id="10023126" />
    </Mention>
    <Mention id="M377" len="29" reason="from_drug_use" section="S1" start="37166" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abnormal liver function tests" meddra_llt_id="10000158" meddra_pt="Liver function test abnormal" meddra_pt_id="10024690" />
    </Mention>
    <Mention id="M378" len="15" reason="from_drug_component" section="S1" start="37204" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatic failure" meddra_llt_id="10019663" meddra_pt="Hepatic failure" meddra_pt_id="10019663" />
    </Mention>
    <Mention id="M379" len="12" reason="from_drug_use" section="S1" start="37228" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatic coma" meddra_llt_id="10019644" meddra_pt="Coma hepatic" meddra_pt_id="10010075" />
    </Mention>
    <Mention id="M380" len="14" reason="from_drug_use" section="S1" start="37249" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatotoxicity" meddra_llt_id="10019851" meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
      <Normalization meddra_pt="Liver disorder" meddra_pt_id="10024670" />
    </Mention>
    <Mention id="M88" len="13" reason="general_term" section="S1" start="37277" type="NonOSE_AE">
      <Normalization meddra_llt="Immune system disorder" meddra_llt_id="10021425" meddra_pt="Immune system disorder" meddra_pt_id="10021425" />
    </Mention>
    <Mention id="M381" len="16" reason="from_drug_use" section="S1" start="37297" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M384" len="30" reason="AE_from_drug_interaction" section="S2" start="558" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder coagulation" meddra_llt_id="10013206" meddra_pt="Coagulopathy" meddra_pt_id="10009802" />
    </Mention>
    <Mention id="M385" len="8" reason="AE_from_drug_interaction" section="S2" start="596" type="NonOSE_AE">
      <Normalization meddra_llt="Bleeding" meddra_llt_id="10005103" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M386" len="5" reason="general_term" section="S2" start="616" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M388" len="29" reason="AE_from_drug_interaction" section="S2" start="814" type="NonOSE_AE">
      <Normalization meddra_llt="Prothrombin time inc" meddra_llt_id="10037060" meddra_pt="Prothrombin time prolonged" meddra_pt_id="10037063" />
    </Mention>
    <Mention id="M389" len="9,3" reason="AE_from_drug_interaction" section="S2" start="814,853" type="NonOSE_AE">
      <Normalization meddra_llt="Uncontrolled INR" meddra_llt_id="10045483" meddra_pt="International normalised ratio increased" meddra_pt_id="10022595" />
    </Mention>
    <Mention id="M383" len="16" reason="preexisting_condition_or_risk_factor" section="S2" start="1151" type="Not_AE_Candidate">
      <Normalization meddra_llt="Liver metastases" meddra_llt_id="10024700" meddra_pt="Metastases to liver" meddra_pt_id="10027457" />
    </Mention>
    <Mention id="M382" len="6" reason="preexisting_condition_or_risk_factor" section="S2" start="1208" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cancer" meddra_llt_id="10007050" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M387" len="12" reason="AE_only_as_instruction" section="S2" start="1273" type="NonOSE_AE">
      <Normalization meddra_llt="Coagulopathy" meddra_llt_id="10009802" meddra_pt="Coagulopathy" meddra_pt_id="10009802" />
    </Mention>
    <Mention id="M427" len="12" reason="AE_from_drug_interaction" section="S3" start="2211" type="NonOSE_AE">
      <Normalization meddra_llt="Coagulopathy" meddra_llt_id="10009802" meddra_pt="Coagulopathy" meddra_pt_id="10009802" />
    </Mention>
    <Mention id="M493" len="8" reason="from_drug_use" section="S3" start="2581" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M428" len="8" reason="AE_only_as_instruction" section="S3" start="2630" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M394" len="6,6" reason="indication" section="S3" start="2779,2800" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M395" len="17" reason="indication" section="S3" start="2789" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer" meddra_llt_id="10061451" meddra_pt="Colorectal cancer" meddra_pt_id="10061451" />
    </Mention>
    <Mention id="M528" len="8" reason="from_drug_use" section="S3" start="2892" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M529" len="8" reason="from_drug_use" section="S3" start="2977" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M429" len="8" reason="AE_only_as_instruction" section="S3" start="3049" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M432" len="49" reason="AE_only_as_instruction" section="S3" start="3075" type="NonOSE_AE">
      <Normalization meddra_llt="Frequent bowel movements" meddra_llt_id="10017367" meddra_pt="Frequent bowel movements" meddra_pt_id="10017367" />
    </Mention>
    <Mention id="M430" len="8" reason="AE_only_as_instruction" section="S3" start="3134" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M433" len="29" reason="AE_only_as_instruction" section="S3" start="3149" type="NonOSE_AE">
      <Normalization meddra_llt="Frequent bowel movements" meddra_llt_id="10017367" meddra_pt="Frequent bowel movements" meddra_pt_id="10017367" />
    </Mention>
    <Mention id="M434" len="12" reason="AE_only_as_instruction" section="S3" start="3182" type="NonOSE_AE">
      <Normalization meddra_llt="Incontinence" meddra_llt_id="10021639" meddra_pt="Incontinence" meddra_pt_id="10021639" />
    </Mention>
    <Mention id="M435" len="13" reason="AE_only_as_instruction" section="S3" start="3199" type="NonOSE_AE">
      <Normalization meddra_llt="Malabsorption" meddra_llt_id="10025476" meddra_pt="Malabsorption" meddra_pt_id="10025476" />
    </Mention>
    <Mention id="M431" len="8" reason="AE_only_as_instruction" section="S3" start="3226" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M436" len="27" reason="AE_only_as_instruction" section="S3" start="3241" type="NonOSE_AE">
      <Normalization meddra_llt="Frequent bowel movements" meddra_llt_id="10017367" meddra_pt="Frequent bowel movements" meddra_pt_id="10017367" />
    </Mention>
    <Mention id="M437" len="23" reason="AE_only_as_instruction" section="S3" start="3272" type="NonOSE_AE">
      <Normalization meddra_llt="Bloody diarrhea" meddra_llt_id="10005872" meddra_pt="Diarrhoea haemorrhagic" meddra_pt_id="10012741" />
    </Mention>
    <Mention id="M438" len="8" reason="AE_only_as_instruction" section="S3" start="3351" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M439" len="8" reason="AE_only_as_instruction" section="S3" start="3437" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M530" len="25" reason="from_drug_use" section="S3" start="3608" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Enterocolitis necrotizing" meddra_llt_id="10055642" meddra_pt="Necrotising colitis" meddra_pt_id="10051606" />
    </Mention>
    <Mention id="M531" len="9" reason="from_drug_use" section="S3" start="3635" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Typhlitis" meddra_llt_id="10045271" meddra_pt="Colitis" meddra_pt_id="10009887" />
    </Mention>
    <Mention id="M532" len="14" reason="from_drug_use" section="S3" start="3696" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiotoxicity" meddra_llt_id="10048610" meddra_pt="Cardiotoxicity" meddra_pt_id="10048610" />
    </Mention>
    <Mention id="M494" len="10,8" reason="from_drug_use" section="S3" start="3741,3763" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial ischemia" meddra_llt_id="10028601" meddra_pt="Myocardial ischaemia" meddra_pt_id="10028600" />
    </Mention>
    <Mention id="M533" len="21" reason="from_drug_use" section="S3" start="3741" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M495" len="6" reason="from_drug_use" section="S3" start="3773" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angina" meddra_llt_id="10002372" meddra_pt="Angina pectoris" meddra_pt_id="10002383" />
    </Mention>
    <Mention id="M496" len="12" reason="from_drug_use" section="S3" start="3781" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysrhythmias" meddra_llt_id="10013978" meddra_pt="Arrhythmia" meddra_pt_id="10003119" />
    </Mention>
    <Mention id="M497" len="14" reason="from_drug_use" section="S3" start="3795" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arrest cardiac" meddra_llt_id="10003109" meddra_pt="Cardiac arrest" meddra_pt_id="10007515" />
    </Mention>
    <Mention id="M498" len="15" reason="from_drug_use" section="S3" start="3811" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiac failure" meddra_llt_id="10007554" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M499" len="12" reason="from_drug_use" section="S3" start="3828" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sudden death" meddra_llt_id="10042434" meddra_pt="Sudden death" meddra_pt_id="10042434" />
    </Mention>
    <Mention id="M500" len="28" reason="from_drug_use" section="S3" start="3842" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Electrocardiogram change" meddra_llt_id="10061116" meddra_pt="Electrocardiogram change" meddra_pt_id="10061116" />
    </Mention>
    <Mention id="M501" len="14" reason="from_drug_use" section="S3" start="3876" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiomyopathy" meddra_llt_id="10007636" meddra_pt="Cardiomyopathy" meddra_pt_id="10007636" />
    </Mention>
    <Mention id="M396" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="3971" type="Not_AE_Candidate">
      <Normalization meddra_llt="Coronary artery disease" meddra_llt_id="10011078" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M426" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="4216" type="Not_AE_Candidate">
      <Normalization meddra_llt="DPD deficiency" meddra_llt_id="10075669" meddra_pt="Dihydropyrimidine dehydrogenase deficiency" meddra_pt_id="10052622" />
    </Mention>
    <Mention id="M440" len="5" reason="general_term" section="S3" start="4329" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M534" len="9" reason="from_drug_use" section="S3" start="4377" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mucositis" meddra_llt_id="10028127" meddra_pt="Mucosal inflammation" meddra_pt_id="10028116" />
    </Mention>
    <Mention id="M535" len="8" reason="from_drug_use" section="S3" start="4388" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M536" len="11" reason="from_drug_use" section="S3" start="4398" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M537" len="13" reason="from_drug_use" section="S3" start="4415" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neurotoxicity" meddra_llt_id="10029350" meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M441" len="5" reason="general_term" section="S3" start="4527" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M502" len="11" reason="from_drug_use" section="S3" start="5108" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M442" len="19" reason="manifestation_or_complication" section="S3" start="5152" type="NonOSE_AE">
      <Normalization meddra_llt="Renal failure acute" meddra_llt_id="10038436" meddra_pt="Acute kidney injury" meddra_pt_id="10069339" />
    </Mention>
    <Mention id="M443" len="5" reason="general_term" section="S3" start="5185" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M397" len="26" reason="preexisting_condition_or_risk_factor" section="S3" start="5219" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal function abnormal" meddra_llt_id="10038451" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M444" len="18" reason="AE_only_as_instruction" section="S3" start="5297" type="NonOSE_AE">
      <Normalization meddra_llt="Drug therapy" meddra_llt_id="10063370" meddra_pt="Drug therapy" meddra_pt_id="10063370" />
      <Normalization meddra_pt="Immunoglobulin therapy" meddra_pt_id="10069534" />
    </Mention>
    <Mention id="M398" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="5350" type="Not_AE_Candidate">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M390" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="5360" type="Not_AE_Candidate">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M391" len="6" reason="preexisting_condition_or_risk_factor" section="S3" start="5370" type="Not_AE_Candidate">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M392" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="5378" type="Not_AE_Candidate">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M393" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="5390" type="Not_AE_Candidate">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M491" len="10" reason="AE_only_as_instruction" section="S3" start="5418" type="NonOSE_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M445" len="11" reason="AE_only_as_instruction" section="S3" start="5498" type="NonOSE_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M446" len="11" reason="AE_only_as_instruction" section="S3" start="5547" type="NonOSE_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M447" len="11" reason="AE_only_as_instruction" section="S3" start="5626" type="NonOSE_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M399" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="5935" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal impairment" meddra_llt_id="10062237" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M400" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="6063" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal impairment" meddra_llt_id="10062237" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M538" len="21" reason="from_drug_use" section="S3" start="6432" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M539" len="10" reason="from_drug_use" section="S3" start="6555" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fetal damage" meddra_llt_id="10054743" meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M401" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="6582" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M402" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="6707" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M448" len="8" reason="AE_animal" section="S3" start="6789" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M449" len="15" reason="AE_animal" section="S3" start="6848" type="NonOSE_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M450" len="14" reason="AE_animal" section="S3" start="6868" type="NonOSE_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M451" len="15" reason="AE_animal" section="S3" start="6895" type="NonOSE_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M403" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="7072" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M540" len="15" reason="from_drug_use" section="S3" start="7104" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M542" len="13,8" reason="from_drug_use" section="S3" start="7318,7349" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mucous membrane disorder" meddra_llt_id="10028133" meddra_pt="Mucous membrane disorder" meddra_pt_id="10028133" />
    </Mention>
    <Mention id="M543" len="21" reason="from_drug_use" section="S3" start="7336" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin toxicity" meddra_llt_id="10059516" meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
      <Normalization meddra_pt="Skin reaction" meddra_pt_id="10040914" />
    </Mention>
    <Mention id="M541" len="23" reason="from_drug_use" section="S3" start="7369" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mucous membrane disorder" meddra_llt_id="10028133" meddra_pt="Mucous membrane disorder" meddra_pt_id="10028133" />
    </Mention>
    <Mention id="M452" len="5" reason="general_term" section="S3" start="7404" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M503" len="24" reason="from_drug_use" section="S3" start="7427" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syndrome Stevens-Johnson" meddra_llt_id="10042849" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Mention>
    <Mention id="M544" len="31" reason="from_drug_use" section="S3" start="7456" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic epidermal necrolysis" meddra_llt_id="10044223" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Mention>
    <Mention id="M461" len="22" reason="AE_only_as_instruction" section="S3" start="7646" type="NonOSE_AE">
      <Normalization meddra_llt="Mucous membrane disorder" meddra_llt_id="10028133" meddra_pt="Mucous membrane disorder" meddra_pt_id="10028133" />
    </Mention>
    <Mention id="M545" len="22" reason="from_drug_use" section="S3" start="7716" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M547" len="33" reason="from_drug_use" section="S3" start="7740" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palmar-plantar erythrodysesthesia syndrome" meddra_llt_id="10054524" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M546" len="35" reason="from_drug_use" section="S3" start="7777" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic erythema of chemotherapy" meddra_llt_id="10074982" meddra_pt="Toxic erythema of chemotherapy" meddra_pt_id="10074982" />
    </Mention>
    <Mention id="M548" len="18" reason="from_drug_use" section="S3" start="7819" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin toxicity" meddra_llt_id="10059516" meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
      <Normalization meddra_pt="Skin reaction" meddra_pt_id="10040914" />
    </Mention>
    <Mention id="M453" len="8" reason="manifestation_or_complication" section="S3" start="8058" type="NonOSE_AE">
      <Normalization meddra_llt="Numbness" meddra_llt_id="10029829" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" />
    </Mention>
    <Mention id="M455" len="11" reason="manifestation_or_complication" section="S3" start="8068" type="NonOSE_AE">
      <Normalization meddra_llt="Dysesthesia" meddra_llt_id="10062872" meddra_pt="Dysaesthesia" meddra_pt_id="10013886" />
    </Mention>
    <Mention id="M454" len="11" reason="manifestation_or_complication" section="S3" start="8080" type="NonOSE_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M456" len="8" reason="manifestation_or_complication" section="S3" start="8093" type="NonOSE_AE">
      <Normalization meddra_llt="Tingling" meddra_llt_id="10043876" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M458" len="17,12" reason="manifestation_or_complication" section="S3" start="8103,8133" type="NonOSE_AE">
      <Normalization meddra_llt="Swelling of hands" meddra_llt_id="10042695" meddra_pt="Peripheral swelling" meddra_pt_id="10048959" />
    </Mention>
    <Mention id="M462" len="17,4" reason="manifestation_or_complication" section="S3" start="8103,8153" type="NonOSE_AE">
      <Normalization meddra_llt="Swelling of feet" meddra_llt_id="10042693" meddra_pt="Peripheral swelling" meddra_pt_id="10048959" />
    </Mention>
    <Mention id="M457" len="21" reason="manifestation_or_complication" section="S3" start="8124" type="NonOSE_AE">
      <Normalization meddra_llt="Erythema" meddra_llt_id="10015150" meddra_pt="Erythema" meddra_pt_id="10015150" />
    </Mention>
    <Mention id="M463" len="8,4" reason="manifestation_or_complication" section="S3" start="8124,8153" type="NonOSE_AE">
      <Normalization meddra_llt="Erythema" meddra_llt_id="10015150" meddra_pt="Erythema" meddra_pt_id="10015150" />
    </Mention>
    <Mention id="M464" len="5,10" reason="manifestation_or_complication" section="S3" start="8140,8165" type="NonOSE_AE">
      <Normalization meddra_llt="Limb discomfort" meddra_llt_id="10061224" meddra_pt="Limb discomfort" meddra_pt_id="10061224" />
    </Mention>
    <Mention id="M465" len="4,10" reason="manifestation_or_complication" section="S3" start="8153,8165" type="NonOSE_AE">
      <Normalization meddra_llt="Pressure feet" meddra_llt_id="10036644" meddra_pt="Limb discomfort" meddra_pt_id="10061224" />
    </Mention>
    <Mention id="M460" len="22" reason="AE_only_as_instruction" section="S3" start="8226" type="NonOSE_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M466" len="16,12" reason="manifestation_or_complication" section="S3" start="8263,8293" type="NonOSE_AE">
      <Normalization meddra_llt="Painful hand" meddra_llt_id="10033508" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M468" len="16,4" reason="manifestation_or_complication" section="S3" start="8263,8313" type="NonOSE_AE">
      <Normalization meddra_llt="Painful feet" meddra_llt_id="10033506" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M467" len="21" reason="manifestation_or_complication" section="S3" start="8284" type="NonOSE_AE">
      <Normalization meddra_llt="Swelling of hands" meddra_llt_id="10042695" meddra_pt="Peripheral swelling" meddra_pt_id="10048959" />
    </Mention>
    <Mention id="M469" len="8,4" reason="manifestation_or_complication" section="S3" start="8284,8313" type="NonOSE_AE">
      <Normalization meddra_llt="Swelling of feet" meddra_llt_id="10042693" meddra_pt="Peripheral swelling" meddra_pt_id="10048959" />
    </Mention>
    <Mention id="M470" len="5,10" reason="manifestation_or_complication" section="S3" start="8300,8325" type="NonOSE_AE">
      <Normalization meddra_llt="Limb discomfort" meddra_llt_id="10061224" meddra_pt="Limb discomfort" meddra_pt_id="10061224" />
    </Mention>
    <Mention id="M471" len="4,10" reason="manifestation_or_complication" section="S3" start="8313,8325" type="NonOSE_AE">
      <Normalization meddra_llt="Pressure feet" meddra_llt_id="10036644" meddra_pt="Limb discomfort" meddra_pt_id="10061224" />
    </Mention>
    <Mention id="M472" len="22" reason="AE_only_as_instruction" section="S3" start="8396" type="NonOSE_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M473" len="18,5" reason="AE_only_as_instruction" section="S3" start="8433,8498" type="NonOSE_AE">
      <Normalization meddra_llt="Desquamation" meddra_llt_id="10012528" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" />
    </Mention>
    <Mention id="M474" len="18,4" reason="manifestation_or_complication" section="S3" start="8433,8511" type="NonOSE_AE">
      <Normalization meddra_llt="Desquamation" meddra_llt_id="10012528" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" />
    </Mention>
    <Mention id="M475" len="10,5" reason="manifestation_or_complication" section="S3" start="8453,8498" type="NonOSE_AE">
      <Normalization meddra_llt="Skin ulcer" meddra_llt_id="10040943" meddra_pt="Skin ulcer" meddra_pt_id="10040943" />
    </Mention>
    <Mention id="M476" len="10,4" reason="manifestation_or_complication" section="S3" start="8453,8511" type="NonOSE_AE">
      <Normalization meddra_llt="Skin ulcer" meddra_llt_id="10040943" meddra_pt="Skin ulcer" meddra_pt_id="10040943" />
    </Mention>
    <Mention id="M477" len="10,5" reason="AE_only_as_instruction" section="S3" start="8465,8498" type="NonOSE_AE">
      <Normalization meddra_llt="Blistering" meddra_llt_id="10005214" meddra_pt="Blister" meddra_pt_id="10005191" />
    </Mention>
    <Mention id="M478" len="10,4" reason="manifestation_or_complication" section="S3" start="8465,8511" type="NonOSE_AE">
      <Normalization meddra_llt="Blistering" meddra_llt_id="10005214" meddra_pt="Blister" meddra_pt_id="10005191" />
    </Mention>
    <Mention id="M479" len="17" reason="manifestation_or_complication" section="S3" start="8486" type="NonOSE_AE">
      <Normalization meddra_llt="Hand pain" meddra_llt_id="10019116" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M480" len="4,4" reason="manifestation_or_complication" section="S3" start="8486,8511" type="NonOSE_AE">
      <Normalization meddra_llt="Sore feet" meddra_llt_id="10041358" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M481" len="5,10" reason="manifestation_or_complication" section="S3" start="8498,8530" type="NonOSE_AE">
      <Normalization meddra_llt="Limb discomfort" meddra_llt_id="10061224" meddra_pt="Limb discomfort" meddra_pt_id="10061224" />
    </Mention>
    <Mention id="M482" len="4,10" reason="manifestation_or_complication" section="S3" start="8511,8530" type="NonOSE_AE">
      <Normalization meddra_llt="Pressure feet" meddra_llt_id="10036644" meddra_pt="Limb discomfort" meddra_pt_id="10061224" />
    </Mention>
    <Mention id="M483" len="52" reason="manifestation_or_complication" section="S3" start="8571" type="NonOSE_AE">
      <Normalization meddra_llt="Activities of daily living impaired" meddra_llt_id="10050954" meddra_pt="Loss of personal independence in daily activities" meddra_pt_id="10079487" />
    </Mention>
    <Mention id="M484" len="22" reason="AE_only_as_instruction" section="S3" start="8646" type="NonOSE_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M490" len="20" reason="manifestation_or_complication" section="S3" start="8712" type="NonOSE_AE">
      <Normalization meddra_llt="Fingerprint loss" meddra_llt_id="10069686" meddra_pt="Fingerprint loss" meddra_pt_id="10069686" />
    </Mention>
    <Mention id="M485" len="22" reason="AE_only_as_instruction" section="S3" start="8792" type="NonOSE_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M486" len="22" reason="AE_only_as_instruction" section="S3" start="8951" type="NonOSE_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M406" len="6,6" reason="indication" section="S3" start="9136,9157" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M407" len="17" reason="indication" section="S3" start="9146" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer" meddra_llt_id="10061451" meddra_pt="Colorectal cancer" meddra_pt_id="10061451" />
    </Mention>
    <Mention id="M504" len="18" reason="from_drug_use" section="S3" start="9314" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M505" len="18" reason="from_drug_use" section="S3" start="9394" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M408" len="18" reason="preexisting_condition_or_risk_factor" section="S3" start="9474" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hepatic metastases" meddra_llt_id="10019690" meddra_pt="Metastases to liver" meddra_pt_id="10027457" />
    </Mention>
    <Mention id="M487" len="18" reason="negation" section="S3" start="9530" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatic metastases" meddra_llt_id="10019690" meddra_pt="Metastases to liver" meddra_pt_id="10027457" />
    </Mention>
    <Mention id="M506" len="18" reason="from_drug_use" section="S3" start="9575" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M549" len="18" reason="from_drug_use" section="S3" start="9675" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M550" len="10,20" reason="from_drug_use" section="S3" start="9730,9792" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alkaline phosphatase increased" meddra_llt_id="10001675" meddra_pt="Blood alkaline phosphatase increased" meddra_pt_id="10059570" />
    </Mention>
    <Mention id="M551" len="27" reason="from_drug_use" section="S3" start="9847" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transaminases increased" meddra_llt_id="10054889" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M409" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="9984" type="Not_AE_Candidate">
      <Normalization meddra_llt="Liver metastases" meddra_llt_id="10024700" meddra_pt="Metastases to liver" meddra_pt_id="10027457" />
    </Mention>
    <Mention id="M552" len="10,13" reason="from_drug_use" section="S3" start="10081,10172" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transaminases increased" meddra_llt_id="10054889" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M553" len="10,20" reason="from_drug_use" section="S3" start="10081,10148" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alkaline phosphatase increased" meddra_llt_id="10001675" meddra_pt="Blood alkaline phosphatase increased" meddra_pt_id="10059570" />
    </Mention>
    <Mention id="M554" len="13,13" reason="from_drug_use" section="S3" start="10250,10288" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transaminases increased" meddra_llt_id="10054889" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M561" len="34" reason="from_drug_use" section="S3" start="10250" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alkaline phosphatase increased" meddra_llt_id="10001675" meddra_pt="Blood alkaline phosphatase increased" meddra_pt_id="10059570" />
    </Mention>
    <Mention id="M410" len="17" reason="indication" section="S3" start="10382" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer" meddra_llt_id="10061451" meddra_pt="Colorectal cancer" meddra_pt_id="10061451" />
    </Mention>
    <Mention id="M555" len="18" reason="from_drug_use" section="S3" start="10431" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M557" len="18" reason="from_drug_use" section="S3" start="10573" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M411" len="17" reason="indication" section="S3" start="10599" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer" meddra_llt_id="10061451" meddra_pt="Colorectal cancer" meddra_pt_id="10061451" />
    </Mention>
    <Mention id="M556" len="25" reason="from_drug_use" section="S3" start="10651" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bilirubin total increased" meddra_llt_id="10056806" meddra_pt="Blood bilirubin increased" meddra_pt_id="10005364" />
    </Mention>
    <Mention id="M412" len="17" reason="indication" section="S3" start="10753" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer" meddra_llt_id="10061451" meddra_pt="Colorectal cancer" meddra_pt_id="10061451" />
    </Mention>
    <Mention id="M558" len="18" reason="from_drug_use" section="S3" start="10798" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M559" len="18" reason="from_drug_use" section="S3" start="10847" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M413" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="10912" type="Not_AE_Candidate">
      <Normalization meddra_llt="Liver metastases" meddra_llt_id="10024700" meddra_pt="Metastases to liver" meddra_pt_id="10027457" />
    </Mention>
    <Mention id="M414" len="13" reason="indication" section="S3" start="10976" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M507" len="18" reason="from_drug_use" section="S3" start="11067" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M508" len="18" reason="from_drug_use" section="S3" start="11131" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperbilirubinemia" meddra_llt_id="10020582" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M492" len="23" reason="AE_only_as_instruction" section="S3" start="11203" type="NonOSE_AE">
      <Normalization meddra_llt="Bilirubin elevated" meddra_llt_id="10004688" meddra_pt="Blood bilirubin increased" meddra_pt_id="10005364" />
    </Mention>
    <Mention id="M488" len="28" reason="AE_only_as_instruction" section="S3" start="11303" type="NonOSE_AE">
      <Normalization meddra_llt="Bilirubin total decreased" meddra_llt_id="10071560" meddra_pt="Blood bilirubin decreased" meddra_pt_id="10049869" />
    </Mention>
    <Mention id="M415" len="6,6" reason="indication" section="S3" start="11494,11515" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M416" len="17" reason="indication" section="S3" start="11504" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer" meddra_llt_id="10061451" meddra_pt="Colorectal cancer" meddra_pt_id="10061451" />
    </Mention>
    <Mention id="M509" len="11" reason="from_drug_use" section="S3" start="11695" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M510" len="16" reason="from_drug_use" section="S3" start="11708" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M511" len="23" reason="from_drug_use" section="S3" start="11728" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemoglobin decreased" meddra_llt_id="10019483" meddra_pt="Haemoglobin decreased" meddra_pt_id="10018884" />
    </Mention>
    <Mention id="M417" len="13" reason="indication" section="S3" start="11799" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M512" len="11" reason="from_drug_use" section="S3" start="11895" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M513" len="16" reason="from_drug_use" section="S3" start="11930" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M514" len="6" reason="from_drug_use" section="S3" start="11974" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anemia" meddra_llt_id="10002272" meddra_pt="Anaemia" meddra_pt_id="10002034" />
    </Mention>
    <Mention id="M418" len="37" reason="preexisting_condition_or_risk_factor" section="S3" start="12007" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neutrophil count decreased" meddra_llt_id="10029366" meddra_pt="Neutrophil count decreased" meddra_pt_id="10029366" />
    </Mention>
    <Mention id="M419" len="38" reason="preexisting_condition_or_risk_factor" section="S3" start="12052" type="Not_AE_Candidate">
      <Normalization meddra_llt="Thrombocyte count decreased" meddra_llt_id="10043546" meddra_pt="Platelet count decreased" meddra_pt_id="10035528" />
    </Mention>
    <Mention id="M489" len="20" reason="AE_only_as_instruction" section="S3" start="12207" type="NonOSE_AE">
      <Normalization meddra_llt="Haematotoxicity" meddra_llt_id="10061188" meddra_pt="Haematotoxicity" meddra_pt_id="10061188" />
      <Normalization meddra_pt="Blood disorder" meddra_pt_id="10061590" />
    </Mention>
    <Mention id="M420" len="6,6" reason="indication" section="S3" start="12439,12460" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M421" len="17" reason="indication" section="S3" start="12449" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colorectal cancer" meddra_llt_id="10061451" meddra_pt="Colorectal cancer" meddra_pt_id="10061451" />
    </Mention>
    <Mention id="M515" len="8" reason="from_drug_use" section="S3" start="12621" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M516" len="6" reason="from_drug_use" section="S3" start="12644" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M517" len="22" reason="from_drug_use" section="S3" start="12665" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M518" len="8" reason="from_drug_use" section="S3" start="12706" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M519" len="8" reason="from_drug_use" section="S3" start="12929" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M520" len="10" reason="from_drug_use" section="S3" start="12942" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis" meddra_llt_id="10042128" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Mention>
    <Mention id="M521" len="22" reason="from_drug_use" section="S3" start="12996" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M422" len="21" reason="indication" section="S3" start="13495" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colon cancer Duke's C" meddra_llt_id="10009949" meddra_pt="Colon cancer stage III" meddra_pt_id="10009955" />
    </Mention>
    <Mention id="M423" len="30" reason="indication" section="S3" start="13523" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colectomy" meddra_llt_id="10061778" meddra_pt="Colectomy" meddra_pt_id="10061778" />
    </Mention>
    <Mention id="M522" len="22" reason="from_drug_use" section="S3" start="13677" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hand-and-foot syndrome" meddra_llt_id="10019126" meddra_pt="Palmar-plantar erythrodysaesthesia syndrome" meddra_pt_id="10033553" />
    </Mention>
    <Mention id="M523" len="8" reason="from_drug_use" section="S3" start="13715" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M524" len="10" reason="from_drug_use" section="S3" start="13739" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis" meddra_llt_id="10042128" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Mention>
    <Mention id="M525" len="11" reason="from_drug_use" section="S3" start="13764" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M560" len="16" reason="from_drug_use" section="S3" start="13776" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Granulocytopenia" meddra_llt_id="10018687" meddra_pt="Granulocytopenia" meddra_pt_id="10018687" />
    </Mention>
    <Mention id="M526" len="8" reason="from_drug_use" section="S3" start="13807" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M527" len="6" reason="from_drug_use" section="S3" start="13833" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M424" len="21" reason="indication" section="S3" start="13981" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colon cancer Duke's C" meddra_llt_id="10009949" meddra_pt="Colon cancer stage III" meddra_pt_id="10009955" />
    </Mention>
    <Mention id="M425" len="30" reason="indication" section="S3" start="14009" type="Not_AE_Candidate">
      <Normalization meddra_llt="Colectomy" meddra_llt_id="10061778" meddra_pt="Colectomy" meddra_pt_id="10061778" />
    </Mention>
    <Mention id="M404" len="19" reason="preexisting_condition_or_risk_factor" section="S3" start="14283" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dysfunction hepatic non-icteric" meddra_llt_id="10057748" meddra_pt="Hepatic function abnormal" meddra_pt_id="10019670" />
    </Mention>
    <Mention id="M405" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="14310" type="Not_AE_Candidate">
      <Normalization meddra_llt="Liver metastases" meddra_llt_id="10024700" meddra_pt="Metastases to liver" meddra_pt_id="10027457" />
    </Mention>
    <Mention id="M459" len="19" reason="AE_only_as_instruction" section="S3" start="14407" type="NonOSE_AE">
      <Normalization meddra_llt="Dysfunction hepatic non-icteric" meddra_llt_id="10057748" meddra_pt="Hepatic function abnormal" meddra_pt_id="10019670" />
    </Mention>
  </Mentions>
</GoldLabel>